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Abstract 
 
One in five people in the U.S. are estimated to experience “any mental illness” (AMI); however this group 
represents an estimated 40% of the annual, adult cigarette consumption in the U.S. Tobacco prevention policies 
have been successful at reducing smoking prevalence among the U.S. population as a whole, however it is 
unclear whether these efforts have had significant impact on tobacco use rates among individuals with AMI. 
The long-term purpose of this project is to reduce the disparity in tobacco use rates for adults with AMI by 
illustrating differences in demand for cigarettes in response to current and potential tobacco prevention policies 
among individuals with and without AMI, and exploring variation in the role of abuse liability as an explanatory 
factor influencing these behavioral responses. 
 
Chapter 1: To investigate whether this disparity in smoking rates might be explained, in part, by variation in 
response to state-level smoking prevention policies over time, we conducted a longitudinal study of 7,842 
young adults who participated in the National Longitudinal Survey of Youth 1997 cohort, modelling 
associations between AMI, tobacco policy, and smoking outcomes and the role of treatment for AMI in 
potentially ameliorating these effects. Our results suggest that, while adults with AMI may be more likely to 
smoke and to have increased cigarette consumption, they do not appear to respond differently to price policies 
than adults without AMI. Our findings offer evidence that current popular tobacco prevention policies may be 
just as effective at reducing smoking among this population, but therefore underscore the need to further 
investigate the role of mental health and tobacco cessation treatment alternatives tailored to the unique needs of 
adults suffering from the dual burdens of both AMI and chronic tobacco use. 
 
Chapter 2: This study addresses a significant gap in our knowledge regarding tobacco use among a population 
of smokers who smoke at higher rates than the general population of U.S. adults, tend to smoke more cigarettes 
and be more dependent on nicotine, and may have additional difficulty reducing or quitting smoking. We 
recruited a sample of 407 adult smokers to investigate whether AMI may moderate associations between price 
policies and demand for cigarettes, and if it may moderate responsiveness of adult smokers to availability of 
alternative products representing different potential regulatory scenarios. In contrast to our study described in 
Chapter 1, where we relied upon secondary data and a more constrained range of price variation, we found that 
smokers with AMI may have less elastic demand for cigarettes in the face of rising prices, and that though they 
are willing to substitute alternative products when cigarettes prices are raised, the extent to which they are 
willing to do so, and whether they do so at rates different from those without AMI, depends on a variety of 
factors. 
 
Chapter 3: Adult smokers with symptoms of any mental illness (AMI) are highly dependent on nicotine and 
may face additional difficulty quitting smoking. Using data from 7,290 U.S. adults who participated in four 
waves of the Population Assessment of Tobacco and Health (PATH) Study, we investigated whether AMI may 
moderate the association between nicotine dependence and use behaviors. Adults with AMI are particularly 
affected by the burden of tobacco use, in part because of the likely interaction between nicotine dependence and 
AMI.  Tobacco control efforts that focus on this interplay may provide an opportunity to better target 
interventions for this vulnerable population. 
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Introduction 
 
 Smoking-related disease remains the leading cause of preventable morbidity and mortality worldwide, 
and account for over 480,000 deaths and approximately $300 billion in annual costs in the U.S alone.1,2 In 2018, 
more than 35 million adults, or approximately 13.7% of the U.S. adult population, were current cigarette 
smokers.3 Between 2005 and 2018 the prevalence of smoking among adults in the U.S. declined by almost 7 
percentage points, from 20.9% to 13.7%.2 However, the prevalence of smoking among adults with any mental 
illness (AMI) remained as high as 36% in 2015, ranging from 18%-49% depending on state of residence.4,5 
 One in five people in the U.S. are estimated to experience “any mental illness” (AMI); however this 
group represents an estimated 40% of the annual, adult cigarette consumption in the U.S.6–9 While tobacco 
prevention and control policies such as taxes and indoor clean air laws have been successful at reducing 
smoking prevalence among the U.S. population as a whole,2,10,11 it is unclear whether these efforts have had 
significant impact on tobacco use rates among individuals with AMI.  Experience of AMI has been linked in 
many previous studies to higher susceptibility to smoke, lower overall rates of cessation,12,13 and reduced 
success when attempting to quit smoking.9,14,15 The U.S. Food and Drug Administration (FDA) has prioritized 
reducing the public health burden of combustible tobacco use, exploring strategies such as reducing nicotine in 
combustible cigarettes to lower their 
addictive potential,16 and evaluating the 
safety of e-cigarettes in comparison to 
combustible cigarettes to inform policy.17 
We have limited knowledge about whether 
these policies will be equally effective for 
those with AMI, or whether they might 
exacerbate an existing disparity. 
 Adults with mental illness or substance use disorders die about 5 years earlier than those without these 
disorders; many of these deaths are caused by smoking cigarettes.18 The most common causes of death among 
people with AMI are heart disease, cancer, and lung disease, for which all smoking is a major contributing 
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factor.19,20  Previous research has identified possible pathways to explain this disparity, including the suggestion 
that adults with AMI are less responsive to tobacco policies (e.g. cigarette taxes), are less likely to quit 
smoking,21 and have higher abuse liability (likelihood of persistent tobacco use or dependence),22,23 than adult 
smokers without AMI. Despite the benefit of this evidence, described in detail in subsequent chapters, much of 
it relies on smaller, non-representative samples, cross-sectional data, or provides limited information that 
requires integration to provide a more robust understanding of whether these policies can reduce the burden of 
smoking among U.S. adults equitably. 
 The long-term purpose of this project is to reduce the disparity in tobacco use rates for adults with AMI 
by illustrating differences in demand for cigarettes in response to current and potential tobacco prevention 
policies among individuals with and without AMI, and exploring variation in the role of abuse liability as an 
explanatory factor influencing these behavioral responses. Abuse liability, or the likelihood of persistent 
tobacco use or dependence,22 may be higher among those with AMI due to use of tobacco, in part, to help cope 
with symptoms of mental illness.9,24,25 Stakeholders such as the Centers for Disease Control (CDC), the 
National Cancer Institute (NCI), and the National Institute on Drug Abuse (NIDA) have identified the 
relationship between AMI and tobacco use behaviors as a top priority,4,25–28 particularly since policy models 1) 
have not sufficiently tested for varying policy efficacy across AMI and non-AMI populations and 2)  have not 
sufficiently explored whether nicotine dependence influences cessation outcomes differently for adults with 
AMI than those without. 
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Conceptual Model 
 
Figure 2. Overview of Conceptual Model 
 
 
 
 
  
 
 
 
  
 
 Guiding this project are the relationships illustrated in Figure 2, Panels A and B, and described in further 
detail in the Background section (below). Panel A illustrates a conceptual relationship between tobacco 
prevention policies, such as excise taxes, clean indoor air laws, education campaigns, and marketing and 
advertising, which seek to reduce tobacco use at the population level, and tobacco consumption decisions by 
individuals over time. If effective, tobacco prevention policies reduce tobacco consumption. However, adults 
with mental illness suffer from adverse symptoms of that illness and consume tobacco to manage symptoms and 
as a coping tool. In this way, mental illness may moderate the effectiveness of policy at reducing tobacco 
consumption for this population. Papers 1 and 2 rely upon the framework described in Figure 2, Panel A, to 
investigate this hypothesis and offer legislators timely information about the effectiveness of tobacco prevention 
policies among a population of adults at high risk for tobacco use. 
  
Panel A: Chapters  1 and 2 
 
Tobacco Consumption 
Decisions 
Tobacco 
Prevention 
Policies 
Mental Illness 
Panel A: Chapters 1 and 2 
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 Figure 2, Panel B illustrates the conceptual framework for the role of nicotine dependence in tobacco 
consumption decisions over time, specifically the choice and ability to successfully quit smoking. Tobacco 
contains nicotine, an addictive chemical that fosters dependence and addiction over time among users, which 
then encourages continued use. An individual’s level of dependence is therefore associated with past, present, 
and future tobacco consumption decisions, including his or her ability to quit smoking if desired. Among adults 
with AMI, use of tobacco fosters dependence in the traditional sense, however use of tobacco as a tool to cope 
with or self-medicate symptoms of mental illness may also mean that AMI moderates the role of dependence in 
its association with tobacco consumption, when compared to the role that dependence plays in tobacco 
consumption choices for adults without AMI. Chapter 3 specifically investigates this question in order to shed 
light on a mechanism that could help explain hypothesized results from Papers 1 and 2. 
 The three papers described in this proposal combined longitudinal, nationally-representative data and 
online behavioral experiments from U.S. adults to compare adult smokers with and without AMI in: 1) historic 
responses to tobacco price policies, 2) responsiveness to different potential tobacco prevention policy scenarios 
federal regulators are currently considering, and 3) the relationship between nicotine dependence and smoking 
cessation.   
 Without understanding whether tobacco prevention and control policies are less effective at reducing 
tobacco use among those with AMI and whether this is, in part, due to differences in the effect of nicotine 
Panel B: Chapter 3 
 
Mental Illness Tobacco Consumption 
Decisions 
Nicotine 
Dependence 
 11 
dependence on behavior, policy makers will continue to struggle to provide equitable and effective tobacco 
prevention policies. 
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Background 
 
Figure 3. Detailed Conceptual Model of Mental Illness, Tobacco Prevention Policy, and Tobacco Use Outcomes 
 
 
Risk Factors for Tobacco Use 
Demographic and 
Socioeconomic Risk Factors 
• Age (Youth/Young 
Adults) 
• Lower Levels of 
Educational Attainment 
and Income 
• Males 
• Non-Hispanic 
Caucasians 
• Peers and/or Family 
who use tobacco  
Tobacco Marketing 
and Advertising 
Mental Illness 
• Need for Coping 
Tool 
• Self-Medication 
Strategies to Manage 
Symptoms 
+ 
Tobacco 
Prevention Policies 
(e.g. Excise Taxes, 
Clean Indoor Air 
Laws, Education 
Campaigns, Bans 
on Youth Access) 
Dependence and 
Addiction 
Preferences for 
Own-Product and 
Level of Use 
• Willingness to 
Pay (WTP) and 
Valuation of 
Own-Product, 
and Alternative 
Products 
+ 
Tobacco Consumption 
Decisions 
Observed Tobacco Use 
• Level of consumption 
over time 
• Price Elasticity of 
Demand 
• Cessation (when 
consumption drops to 
zero) 
Theoretical Purchasing 
Behavior 
• Observed Demand for 
Own-Product 
• Price Elasticity of 
Demand 
Theoretical Purchasing 
Behavior 
• Observed Demand 
for Alternative 
Tobacco Products 
• Cross-Price 
Elasticity of Demand 
+
v 
+
v 
- 
Genetic 
Predisposition 
+
v 
+
v 
+
v 
+
v 
Mental Health 
Treatment 
- 
- 
+
v 
+
v 
 13 
Figure 3 (above) offers more detailed insight into the theoretical and practical associations between mental 
illness and smoking behavior that have guided this project. There are a number of general demographic and 
socioeconomic risk factors for initiating and continuing tobacco use for which we now have strong base of 
evidence. Evidence suggests that youth and young adults, males, those with lower education and income, and 
those with family and friends who use tobacco all face enhanced risk for initiating and continuing smoking 
behavior.29 Exposure to tobacco advertising and marketing, as well as receptivity to tobacco advertising, is also 
significantly associated with higher rates of tobacco product initiation.29–34 
 In addition to these broadly-applicable risk factors for smoking, youth and adults suffering from mental 
illness also face enhanced risk for initiating and continuing smoking.5,19,20,24,35 Risk factors for mental illness 
include having a parent or relative with a mental illness, experiencing stressful or traumatic life events, 
experiencing an ongoing medical condition, being abused or neglected, and social isolation.36 In addition, 
genetic predisposition plays a role in influencing both the risk of developing mental illness, and the risk of 
becoming dependent on substances of abuse.36,37 Youth and adults suffering from mental illness symptoms, as 
well as all individuals, make choices about their health behavior based on their beliefs about the likely 
consequences of those actions. This proposal relies upon a health belief model to illustrate why adults choose to 
smoke, and why adults suffering from mental illness symptoms smoke at higher rates,5 and smoke with 
increased intensity compared to those who do not suffer from these symptoms.38  
 A health belief model describes how individuals rely on positive expectancies and negative expectancies 
about the consequences of engaging in a health behavior to guide their decision-making. Positive expectancies 
about the effects of smoking include pleasure, reduction of stress, reduction of withdrawal symptoms, energy, 
improved social image and weight control or reduction. Negative expectancies include negative social image, 
reduced social acceptance, harm to immediate or long-term health, smelling bad, causing harm to others, and 
becoming addicted.39 Previous research on smoking expectancies among youth,40 adults,41,42 and adults with 
mental illness37 has identified that adults experiencing mental illness are unique in that they report the positive 
expectancy “reduction of negative affect” as most important factor in guiding their decisions about smoking.42–
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45 Negative affect refers to adverse symptoms they experience due to mental illness. Smoking, therefore, is one 
tool of many that adults with mental illness may rely upon to cope with their symptoms.a  
 In addition to the influence of genetic and personal factors in their association with mental illness 
symptoms and smoking outcomes, evidence, albeit conflicting, has emerged regarding the role of receiving 
mental health treatment and these outcomes.  Some recent evidence has suggested that adults with mental 
illness who are receiving treatment may be more likely to be able to reduce and cease smoking.5 This makes 
intuitive sense, as the goal of treatment is to reduce the types of negative emotions and symptoms experienced 
by adults with AMI. As previous research has suggested, many smokers with AMI have rated “reduction of 
negative affect” i.e. negative mood symptoms as their most important positive expectancy in regard to their 
smoking behavior. If treatment could reduce such symptoms, it follows logically that this could also reduce the 
need for a tool such as smoking to help cope with those symptoms. However, other recent evidence has 
suggested that adults with AMI who received treatment smoked at rates no different than their peers who had 
not been treated.35 While a number of studies have sought to characterize differences in smoking behavior 
among those with and without AMI, as well as across a spectrum of mental illness diagnoses, very few studies 
have specifically examined this factor in explaining differences in smoking and cessation rates among adults 
with AMI, and the evidence we have available conflicts. If treatment has a positive impact on symptoms of 
AMI, our expectation would mirror results from the first study mentioned above, and smokers with AMI who 
receive treatment should experience a reduction in symptoms of AMI, therefore the impact of AMI on tobacco 
consumption should be reduced. 
 Economic models of addiction can also be particularly helpful in shaping our expectations about the 
relationships between mental illness, dependence and addiction, tobacco prevention and control policies, and 
smoking behavior outcomes.46 Cigarettes contain nicotine, an addictive chemical that encourages continued use 
after initiation of smoking;47 continued use of cigarettes fosters both behavioral and physical dependence, 
 
a Previous research has also described the role of the tobacco industry in positioning cigarettes as a tool to cope with mental illness or 
stress symptoms, and to self-medicate.24,69 Internally-funded and externally-funded research by tobacco companies suggested that 
adults with mental illness need to smoke to cope with their symptoms, and that cigarettes could be used to self-medicate and reduce 
symptoms. Marketing messages appealing to those with mental illness, as well as close ties between tobacco manufacturers and 
behavioral health practitioners also contributed to this pervasive public perception of cigarettes as a positive tool for coping. 
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leading to addiction. Economic models of addiction include 1) rational models of addiction, in which 
individuals make consumption decisions with perfect foresight about the future consequences of past and 
current consumption, 2) myopic models of addiction, in which individuals make decisions about current 
consumption that ignore the effects of past and current consumption on future consumption, and 3) imperfectly 
rational models of addiction, in which individuals are conflicted about choosing current consumption since 
choices that maximize their future well-being may be different than those which maximize their current well-
being.48 Critiques of economic addiction models abound, as individuals may underestimate their individual 
likelihood of addiction when making consumption choices, and the effects of addiction may vary across 
individuals.49 Despite these critiques, economic models of addiction can adapted to explain how individuals 
make choices about cigarette consumption, and our expectations about how policy may influence preferences 
regarding consumption. 
 Estimating demand for cigarettes in response to tobacco prevention policy strategies requires that the 
addictive nature of cigarettes, and their utility as a strategy for coping with mental illness, be accounted for in 
order to model these relationships as accurately as possible. For example, the rational addiction model assumes 
that all individuals wish to maximize their well-being (utility) over time, and that their consumption choices 
fluctuate in response to what they consider marginal benefits and harms (or costs) of those choices. By 
consuming an addictive good such as cigarettes, smokers build up an addictive stock over time, which 
influences their utility and preferences. Rational addiction models include three critical elements of addiction 
and addictive stock to help explain consumption choices: tolerance, withdrawal, and reinforcement. Tolerance 
refers to the tendency for smokers to habituate to a specific level of nicotine consumption, suggesting that 
smokers therefore require increasing levels of nicotine over time to maintain the same level of utility, otherwise 
they risk withdrawal. Withdrawal refers to negative physical and psychic symptoms experienced when an 
individual consumes less nicotine than the level to which they are currently accustomed. If an individual gains 
utility from smoking in the current period, reducing consumption would risk reduced utility through the 
experience of withdrawal. Finally, reinforcement occurs when consumption choices help the smoker maximize 
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utility in the past and current period by avoiding negative states such as withdrawal, through continued smoking 
and contribution to his or her addictive stock.46,50  
 This description of an economic model of addiction, and the debate about proper assumptions 
underlying these models, has been simplified, however several important insights surface regarding the role of 
dependence, addiction, and tobacco prevention policies in influencing smoking behavior and how these 
influences may differ across adults with and without mental AMI. Figure 3 offers a visual description of our 
expectation that, based on the addictive nature of tobacco products, initiation and continued use should increase 
an individual’s dependence and addictive stock, and motivate them to maximize utility by continuing to smoke. 
If an individual with mental illness has higher risk for being more dependent on cigarettes than an individual 
who does not suffer from these symptoms,5 then those suffering from mental illness may get more utility from 
smoking and be less likely to reduce smoking behavior. Additionally, tobacco prevention policies should 
influence smokers’ preferences and valuation of their smoking behavior by increasing the costs borne by 
smokers when they choose to smoke (both monetary and time costs), as well as making the health consequences 
of smoking more salient through public health and counter-advertising campaigns. Evidence suggests that price 
policies such as taxes, and non-price policies such as clean indoor air laws and information campaigns, have 
been successful over the past several decades at increasing the “cost” of smoking in relation to its benefits for 
addicted smokers.29,51–54 One insight from economic models of addiction is that the degree of policy response is 
expected to be proportional to the level of increased “cost” policies impose on smokers relative to the level of 
positive marginal utility each smoker receives by maintaining their current consumption.  
 Chapter 1 describes our investigation of the role of price policy in changing consumption of cigarettes 
over time, with a specific focus on whether smokers suffering from any mental illness may be less responsive to 
increases in the costs of consumption.  Chapter 2 describes the role of several prospective alternative tobacco 
prevention policies in influencing smokers’ preferences for consumption of their own tobacco product. Finally, 
Chapter 3 describes the role of dependence in moderating smoking behavior among smokers with symptoms of 
mental illness. Taken together, these three studies offer needed insight into key pathways in the conceptual 
model described above, with the goal of offering insight to policymakers struggling to craft equitable and 
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effective tobacco prevention policies. 
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Chapter 1 Associations Between Mental Illness and Variation in Response to 
Cigarette Price Policy Among U.S. Adults. 
 
Abstract 
 
Background: Policy alternatives such as excise taxes on the purchase of cigarettes, indoor clean air laws, youth 
access laws, cessation support, and public information campaigns are all widely agreed to be significant 
contributors to the decline in smoking rates over time.29 However, the extent to which smoking prevention 
policies, particularly cigarette taxes, are equally effective across sub-populations of smokers is still a focus of 
debate. 
Methods: 7,842 participants who participated in 5 rounds of data collection (2002, 2004, 2006, 2008, 2010) for 
the National Longitudinal Survey of Youth 1997 cohort answered questions about both mental health and 
smoking behavior. Fixed-effects linear probability and Poisson models were fit to the data, modeling 
associations between AMI, cigarette price, and 1) the likelihood of smoking participation, 2) cigarette 
consumption, conditional upon participation.  
Results: Adults who experienced AMI were 4 percentage points more likely to report smoking since the date of 
last interview (ß=0.04, 95% CI: 0.02, 0.05), and having AMI was associated with a 10.5% increase in CPD and 
an 11.6% increase in total consumption compared to participants with no AMI (ß=0.10, 95% CI:0.01, 0.16; 
ß=0.11, 95% CI:0.06, 0.16, respectively). Among participants with AMI, whether they reported receiving any 
treatment for AMI from a health professional was a positive predictor of increased smoking participation and all 
consumption outcomes. 
Conclusions:  While adults with AMI may be more likely to smoke and to have increased cigarette 
consumption, they do not appear to respond differently to price than adults without AMI. As excise taxes on 
cigarettes are a common policy tool widely considered to reduce smoking among youth and adults, this offers 
positive indications that such policies may prove equally effective at doing so among this population, rather 
than contributing to a growing gap in prevalence of use compared to the general population of U.S. adults.   
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Introduction  
 
 Policy alternatives such as excise taxes on the purchase of cigarettes, indoor clean air laws, youth access 
laws, cessation support, and public information campaigns are all widely agreed to be significant contributors to 
the decline in smoking rates over time.29 However, the extent to which smoking prevention policies are equally 
effective across sub-populations of smokers is still a focus of debate. Much of the literature on this topic has 
focused on youth,55–58 as the majority of cigarette smoking originates in youth and young adulthood,29,59 or on 
the association between prevention policies and income,60–62 as many argue that the burden of cigarette excise 
taxes in particular may disproportionately burden low-income adults. Despite this evidence, a still-limited body 
of work exists to inform policymakers about the response to these policies by another group of individuals 
highly vulnerable to initiating and continuing smoking: adults with symptoms of mental illness.  
 In 2018, 19.1% of U.S. adults had experienced any mental illness (AMI) in the previous 12 months, and 
4.6% experienced serious mental illness (SMI);b both rates were higher in 2018 than they had been in most 
years during the previous decade.63 Adults with AMI are significantly more likely to report current cigarette use 
than adults without these disorders (28.1% vs. 16.3% in 2018),21,63 to smoke more cigarettes,64,65 have higher 
nicotine dependence,66,67 and to suffer from early mortality due to tobacco-related disease.18,67,68 The prevailing 
theory regarding the link between AMI and smoking behavior is based on use of cigarettes and nicotine by 
adults with AMI who believe cigarettes to be a helpful behavioral or chemical tool to self-medicate when 
coping with symptoms of AMI, a theory both supported by tobacco industry-funded research and exploited in 
advertising efforts.45,68,69 Evidence supports the reverse: use of cigarettes may exacerbate symptoms of AMI and 
reducing or quitting smoking is associated with an amelioration of symptoms.68 Within this group of adults, the 
prevalence of smoking also varies widely across a variety of factors: prevalence of smoking has been estimated 
to be as high as 40%-60% among adults with depression, and 45%-88% among adults with schizophrenia,70 and 
 
bAMI was defined as experiencing an emotional, behavioral, or mental disorder that met DSM-IV criteria; SMI classification includes 
that stipulation that the disorder ‘substantially interfered’ with at least ‘one major life activity.’ The AMI category does not include 
individuals with substance abuse or developmental disorders.63 
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overall smoking rates among adults with AMI across states ranged from 18% (Utah) to 49% (West Virginia) 
across states.4   
 While regulated at the federal level, authority to implement smoking prevention policies is also 
devolved to individual states, leading to significant variation in the extent of smoking prevention efforts across 
states.71 Levying excise taxes on the purchase of cigarettes is a common policy tool employed at both the 
federal and state level to prevent or reduce tobacco use, among other goals, and the shared authority to regulate 
excise taxes leads to wide variation in tax rates (the lowest rate in 2020 was $0.17 in Missouri, the highest $4.35 
in New York).29,46,52,72 Price responsiveness, or own-price elasticity of demand, is an important outcome to 
measure when assessing the effectiveness of taxes in reducing tobacco use, as these elasticity estimates 
represent how much smoking was reduced, or anticipated to be reduced, for a given increase in price.46 
Evidence reviews on price elasticity of cigarette demand in the U.S. typically offer estimates between -0.3 and -
0.5,55 representing an estimated decrease in purchase of cigarettes of 3%-5% for every 10% increase in the cost 
of cigarettes. However, tax rates effective at the population level may not be equally impactful across specific 
populations, as not all individuals may respond to increases in price in exactly the same way.53,61,73,74 For 
example, one study found that smokers experiencing financial stress had a lower price elasticity of demand for 
cigarettes, which means that despite having more limited resources to purchase cigarettes, adults experiencing 
financial stress were less likely than their non-stressed counterparts to reduce smoking behavior at a similar rate 
when faced with rising prices.73 Additional studies have focused on factors such as age,53–55,75–78 and race and 
ethnicity53,57,79 to investigate variation in response among individuals, and at the population level, to price 
increases over time. Findings from these studies suggest that youth may have a higher price elasticity of demand 
for cigarettes than adults, which could be attributable to factors such as lower spending power than adults and 
lower levels of addiction in the early stages of cigarette use.29,55  
 While there is a robust body of literature on price elasticity of demand for cigarettes among youth and 
adults, there is little evidence documenting whether cigarette taxes are equally effective at reducing smoking 
among individuals with AMI,48,74,80 and the evidence thus far provides conflicting answers on this point. One 
study explored the association between conventional cigarette price elasticity of demand and AMI among a 
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national sample of youth only, using depression and suicidality as measures of AMI.48 The study’s authors 
found youth with suicidality symptoms to have less elastic demand for cigarettes than  non-suicidal youth 
(although the magnitude of this difference was small), a finding which conflicts with results from nationally-
representative data suggesting that youth with behavioral or emotional problems were at least as responsive to 
price as those without such disorders.80  
Among the limited studies focusing on adults with AMI, there are also conflicting conclusions. A 
foundational study by Saffer and Dave (2006) used a nationally-representative cross-sectional sample of adults 
from 1991, and found that adults with a past-year or lifetime diagnosis of mental illness had a less elastic 
demand for cigarettes than those without such diagnoses, but, again, this difference was small.74 In contrast, 
another study surveying U.S. adults with alcohol, drug, and/or mental disorders (any behavioral health 
disorder), found that a 10% increase in price was associated with an 18% reduction in smoking participation,81 
which is significantly higher than the 3%-5% range offered based on many previous studies based upon general 
population data. This finding has been replicated outside of the U.S. as well: among Taiwanese adults, 
symptoms of depression were associated with more elastic cigarette demand than that of adults without such 
symptoms.82 
 Finally, adults with AMI may find relief from some of their symptoms as a result of participation in 
treatment for AMI, which could reduce dependence on cigarettes as a coping tool and increase success in 
reducing or quitting cigarette use.5 This is particularly important in light of the heavy health burden of smoking 
within this particular population, as well as the financial implication of higher costs of smoking among a group 
of adults who may be prone to both lower levels of income and potentially less elastic demand in the face of 
rising prices.67,83,84 In order to more effectively carry out policy efforts to reduce smoking among U.S. adults 
with AMI, without unintentionally exacerbating this disparity through the use tobacco control policy tools such 
as increases in excise tax rates, we still require generalizable, longitudinal information about whether adults 
with AMI have a lower price elasticity of cigarette demand than adults without such symptoms. We also require 
further investigation of the role of treatment for AMI in moderating the relationship between symptoms of AMI 
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and initiating and continuing cigarette consumption. Both of these outcomes are particularly important to 
understand in young adulthood, as 98% of smokers try their first cigarette by the age of 26.85 
 This study employed longitudinal, nationally-representative data from a cohort of approximately 7,000 
adult participants from 5 waves of the National Longitudinal Survey of Youth 1997 (NLSY97) geo-coded data 
to investigate whether young adults with AMI have been equally as responsive to increases in the cost burden of 
smoking, or whether a lower price elasticity of demand for cigarettes may help illuminate one possible reason 
for the persistence of a disparity in smoking rates for this group. Additionally, we offer insight into whether 
receiving treatment from a mental health provider is associated with variation in smoking behavior.  
Conceptual Model 
 
 
 
  
 
 
 
 
 
 
 
  
 
  
 
 This study focused on the associations between mental illness, tobacco prevention and control policies, 
smoker’s preferences, and observed tobacco consumption over time, as illustrated in the detailed conceptual 
framework in Figure 3. Based on the conceptual model, a price policy such as an increase in the excise tax on 
cigarettes should increase the cost of smoking faced by the smoker, reducing some of the benefit (utility) a 
smoker receives from consumption. If smokers with mental illness rely on smoking to help cope with symptoms 
of mental illness, their preferences for maintaining consumption of cigarettes may be stronger, leading to a 
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lower price elasticity of demand than smokers without such symptoms (more reluctance to reduce smoking in 
the face of higher prices over time). However, use of mental health treatment should reduce these symptoms of 
mental illness, therefore potentially mitigating the expected positive association between mental illness and 
tobacco use. 
Hypotheses  
  
 H1a: Demand for cigarettes among adults with AMI will be less responsive to changes in cigarette 
prices due to excise taxes than those without AMI, reflected by a lower price elasticity of demand. 
 H1b: Receiving treatment by a mental health professional will be associated with lower probability of 
smoking participation, and with reduced cigarette consumption. 
 
Methods 
 
Sample 
 The National Longitudinal Survey of Youth (NLSY) is a nationally representative, longitudinal cohort 
study administered by the U.S. Bureau of Labor Statistics (BLS). Confidential, geo-coded data was obtained 
from BLS to allow the addition of policy variables for each participant, such as the excise tax rate in every state 
each year, and presence of other state-based tobacco prevention policies to which they would have been subject 
and would have influenced the tobacco use policy environment in which they resided (e.g., youth access laws, 
clean indoor air laws and state-level tobacco prevention funding over time; see below).  
 8,984 individuals born between 1980 and 1984 were interviewed in Round 1 (1997) of the NLSY97 
sample and are interviewed annually, data collection is ongoing. The NLSY97 cohort is was selected based on a 
multi-stage area probability design and is made up of two sub-samples: a cross-sectional sample (n=6748) 
designed to be nationally-representative of the U.S. population at Round 1, and a supplemental sample 
(n=2,236) which oversampled Hispanic or Latino and African American residents.c At round 18 (2017-2018), 
nearly 75% of Round 1 participants responded. Our analytical sample included the 7,842 participants who 
participated in the 5 rounds of data collection (2002, 2004, 2006, 2008, 2010) during which all participants were 
 
c For more information, see the NLSY97 Technical Sampling Report.182 
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ages 18+, and which included questions about both mental health and smoking behavior, and for which 
comparable smoking prevention policy data were available to add to our analytical data set.86,87  
Smoking Behavior Measures 
 
 Based on the distribution of our outcomes over time and best practices from previous research in this 
field,53,88,89 we estimated our models in two stages: 1) the probability of smoking participation (Yes/No), and 2) 
given smoking participation, the price elasticity of demand for cigarettes, calculated as the percent change in 
quantity demanded of cigarettes per 10% increase in the price of cigarettes (see Statistical Analysis, below, for 
further detail).  Demand for cigarettes can be defined in multiple ways, such as the number of days smoking 
cigarettes within the previous month, and the number of cigarettes smoked per day on the days smoking 
occurred.48,53 This study used a monthly, continuous measure of total cigarettes smoked in the past 30-days to 
estimate demand, consistent with previous models.48 We also examined whether our main parameters of interest 
were robust to variation in the measurement of demand, by estimating models where cigarettes smoked per day 
(CPD) and number of days smoking cigarettes were alternative outcomes.  While mental health questions were 
only asked in selected years (see below), a monthly, continuous measure of cigarette consumption was available 
for all participants for rounds 1-17 of data collection. As mentioned above, we included smoking data from the 
5 waves in which both mental health and smoking indicators were available. 
Any Mental Illness (AMI) Measures 
 
 The Mental Health Inventory (MHI-5) was administered to all participants starting in Wave 4 (2000), 
and asked them to rate how much of the time during the past month they experienced five different mental 
health states (both positive and negative), with a 4-item response scale from “All of the time” to “None of the 
time.” Higher scores indicate better mental health, thus the two positive mental health state questions were 
reverse coded to be congruent with scoring guidelines.90,91 The Cronbach’s alpha score for scale reliability was 
0.79, indicating acceptable reliability for our analyses.92 To score the MHI-5, individual question scores are 
added together, then normalized to create a score ranging from 0-100, with lower scores indicating greater 
mental health distress over the previous month. The appropriate clinically relevant threshold for indicating high 
likelihood of having AMI and needing services is still a subject of debate. Our study relied upon the traditional 
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threshold score of 60 (those with scores under 60 in each wave were recorded as having AMI),90,91 however 
alternative thresholds have been proposed based on different method of classification (Youden Index, 0/1 
method, minimax method).91 We also tested the sensitivity of our model outcomes to these alternative 
thresholds (see Discussion and Appendix 1-A). 
 Additionally, all participants were asked in Round 14 (2010) how many times in the past 12 months they 
‘had an emotional, mental or psychiatric problem’ and were treated by a mental health professional. A three-
level categorical variable for treatment was created (No AMI, AMI and no treatment received, and AMI with 
one or more visits for treatment).  
Price and Tobacco Policy Measures 
 
Price policies: While previous studies have used a variety of specifications to represent price such as 
real, average price for a pack of cigarettes, or excise tax rate in each locality,88 our models were estimated by 
defining price as the excise tax rate facing each participant by state and year, as previous authors have 
suggested this might be the most appropriate measure of variation in price, as state excise tax rates are not 
subject to market forces.76 This data is available from The Tax Burden on Tobacco, a publicly available report 
published each year by Orzechowski and Walker.86 We indexed excise tax rates to 2002 US dollars using the 
Average Annual Consumer Price Index-All Urban Consumers to provide comparable estimates of change 
across time,93and used a natural log transformation to estimate an elasticity as the change in log consumption 
based on change in log of the real tax rate.89  
Non-price policy variables: Additionally, an index describing the comprehensiveness of each state’s 
tobacco prevention policies was included in our models to help isolate the effects of tax policy by controlling 
for other factors influencing the policy environment for smoking in each state over time.87 The American Lung 
Association provides a publicly-available, annual State of Tobacco Control (SOTC) report that scores each state 
based on the comprehensiveness of its tobacco control policy compared to widely-accepted best practices.94 
Each factor score is a summary measure based on a state’s performance across a number of sub-categories (see 
Appendix 1-B). Individual SOTC category scores have been validated in a previous investigation to be 
significantly, negatively correlated with state mortality amenable to tobacco.87 
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We created an index for tobacco control by standardizing each state’s score per category in each survey 
period (z-score transformation), and adding each policy category z-score to create an individual total tobacco 
control index score per state in every survey period.87 While the previous study cited,87 and the SOTC reports, 
also include a category for state excise tax rate, we omitted this from our tobacco control index as we include 
tax rate as a separate variable  in our models. We tested the sensitivity of our main models to including SOTC 
excise tax rate scores in the tobacco control index and found our parameters of interest similar when excluding 
this factor. 
Covariates 
 
 Covariates included time-variant demographic factors associated with variation in smoking behavior,2,29 
such as age category (18-20, 21-25, 26-30), highest level of educational attainment (measured as No Degree, 
HS Diploma or GED Equivalent, Some College/Associate Degree, Bachelor’s degree or higher), and average 
annual household income (Less than $12,400, $12,401-$37,499, $37,500-$73,499, $73,500+).  
 
Statistical Analysis 
 
 We estimated our models in two stages:53,88,89 
1. Smoking Participationit = ß(AMIit) + ηln(taxgt) + λ(AMIit x lntaxgt) + XiΩ + Ζgtγ + εigt 
2. Consumption|Smokingit = ß(AMIit) + ηln(taxgt) + λ(AMIit x lntaxgt) + XiΩ + Ζgtγ + εigt 
Where Χ is a matrix of time-variant individual factors and Ζ is a matrix of state-level factors such as the 
strength of additional tobacco prevention policies, ß, η, λ are parameters to be estimated. Our hypotheses predict 
that λ will be both positive and statistically significant. 
Modelling these outcomes separately is a strategy that has been used frequently in previous studies to 
help account for the distribution of outcomes among participant sample,89 as the more limited frequency of 
smoking would introduce a number of 0 or missing results into the second model where we estimate parameters 
for cigarette consumption based on price. For our main models pictured above, we used biannual data from 
2002-2010. Both models employed person-level fixed effects to control for unobservable time-invariant 
heterogeneity at the individual participant level, and heteroskedasticity-robust standard errors clustered at the 
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individual level.95 Model 1 was estimated with data from the full analytic sample, using a linear probability 
model to estimate the association between likelihood of smoking participation across time, AMI, cigarette price, 
an interaction between AMI and price, and time-variant sociodemographic covariates. In Model 2, we further 
accounted for distribution of our limited dependent variables by employing a Poisson model with 
heteroskedasticity-robust standard errors, a generalized linear model with strengths in regard to modeling count 
data (number of cigarettes smoked, number of days smoked, total number of cigarettes consumed), as well as 
non-negative continuous data with skewed distribution of outcomes.96,97 Cross-sectional survey weights were 
used to account for design effects and provide a nationally-representative description of the sample in period 
one of the study (2002). 
 To model the association between our smoking behavior outcomes, AMI, treatment for AMI, and 
covariates, we also estimated Models 1 and 2 with no person-level fixed effect, as only one time period was 
available for this analysis (2010), however this allowed us to include time-invariant characteristics such as sex 
and race/ethnicity (defined in the survey as Caucasian, Black or African American, Hispanic, or Mixed Race) in 
our models. Cross-sectional survey weights were used to account for design effects and to offer nationally 
representative estimates from our single-period treatment models (2010). All analyses were performed using 
Stata 16 (College Station, TX). 
Results 
 
Weighted Characteristics of Sample Participants at the Beginning of the Study Period (2002) 
 
 In 2002, a majority (53.6%) of study participants reported no smoking participation (95% CI: 52.0, 55.2; 
Chapter 1- Table 1). Among smokers, the mean number of cigarettes smoked per day within the past 30-days 
was 9.3 (SE: 0.23), the number of days smoking cigarettes in the past 30-days was 19.1 (SE: 0.25); mean total 
monthly consumption was 256.1 cigarettes (SE: 6.85) within the previous month. Most participants (76.3%, 
95% CI: 75.3, 77.3) did not exhibit an MHI-5 score that indicated symptoms of AMI, and the mean U.S. 
cigarette excise tax rate facing all participants was $0.69 (SE: 0.02). From a sociodemographic perspective, 
there were more male participants (51.2%, 95% CI: 49.8, 52.6) than female, most participants were ages 18-20 
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years of age (59.7%, 95% CI: 58.6, 60.7), Caucasian (70.5%, 95% CI: 68.4, 72.5), and had received High 
School diploma or GED equivalent (75.4%, 95% CI: 74.2, 76.7). 
Associations Between AMI, Excise Taxes, Tobacco Control Policies, and Smoking Behavior 
 
 Modelling the association between cigarette price and smoking participation revealed that, without 
adjusting for AMI status, other tobacco prevention policies, or covariates, a 10% increase in excise tax was 
associated with a 0.2 percentage point decrease in the probability of smoking participation (ß=-0.02, 95% CI: -
0.04, -0.02) (Table 1-2, Column 1). Adding our measure for AMI revealed that having AMI was associated with 
a 3 percentage point increase in the probability of smoking (ß=0.03, 95% CI: 0.02, 0.04), and tax remained 
statistically significant with an association of the same magnitude as in the first model (Table 1-2, Column 2). 
Adding interactions between AMI and price and the strength of other tobacco prevention policies did not impact 
the magnitude or significance of price parameters, however the magnitude of the positive association between 
AMI and smoking rose from 3 percentage points to 4 (ß=0.04, 95% CI: 0.02, 0.05). Once the model was fully 
saturated, having AMI was associated with a 4-percentage point increase in the probability of smoking since the 
date of last interview (ß=0.04, 95% CI: 0.02, 0.05). The association between excise tax rate and smoking 
participation was still negative as expected, as was our tobacco control index parameter, but the magnitude of 
the association was reduced (ß=-0.01, 95% CI: -0.02, -0.00), and it was no longer statistically significant. We 
hypothesized that the interaction between AMI and price would be both positive and statistically significant; 
while positive, it was not significantly associated with variation in likelihood of smoking participation. Finally, 
in the saturated model, participants were also 6 percentage points less likely to report smoking participation in 
2010 compared to 2002 (ß=-0.06, 95% CI: -0.08, -0.03), and while not statistically significant, increased age 
and higher educational attainment were associated with lower probability of smoking. 
 For two of our consumption measures, total consumption and cigarettes smoked per day (CPD), we 
observed a similar pattern, whereby AMI was significantly association with outcomes, but price and our 
interaction term were not (Table 1-3). Having AMI was associated with a 10.5% increase in CPD and an 11.6% 
increase in total consumption compared to participants with no AMI (ß=0.10, 95% CI:0.01, 0.16; ß=0.11, 95% 
CI:0.06, 0.16, respectively). While our hypothesis that an interaction between AMI and price would be positive 
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held true, it was not statistically significant, nor were the negative associations between price and tobacco 
control policies and these behaviors. Regarding number of days smoking, having AMI was not associated with 
significant variation, however a 10% increase in state excise tax rate was significantly associated with a 0.2% 
decrease in number of days smoked (ß=-0.02, 95% CI: -0.03, -0.01) across all participant groups. Contrary to 
our hypothesis, the association between number of days smoking and an interaction between AMI and price was 
both negative and not statistically significant. Though not statistically significant, we observed that increased 
age was associated with greater consumption of cigarettes and more frequent use, whereas higher income was 
associated with reduced consumption, and higher education associated with fewer CPD and lower total 
consumption. 
Weighted Associations Between Treatment for AMI and Smoking Behavior 
 
 Among participants with AMI, whether they reported receiving any treatment for AMI from a health 
professional was a positive predictor of increased smoking participation and all consumption outcomes 
compared to those with no AMI and no treatment, however differences between those with AMI who did and 
did not receive treatment were not uniformly significant across outcomes (Table 1-4). For example, compared 
to those without AMI, those with AMI who received no treatment were 11 percentage points more likely to 
report smoking participation (ß=0.11, 95% CI: 0.08, 0.14), and those with both AMI and any treatment over the 
previous months were 15 percentage points more likely to report smoking than those with no AMI (ß=0.15, 
95% CI: 0.07, 0.23).  However, an adjusted Wald test revealed that we could not reject the null hypothesis that 
these two coefficients were equal.   
 Similarly, all cigarette consumption outcome revealed no significant differences between those with or 
without AMI and no treatment, the only significant coefficients were those estimating differences between no 
AMI versus those with AMI who had received treatment. Having AMI and receiving treatment was associated 
with a 10.5% increase in the number of days smoking (ß=0.10, 95% CI: 0.04, 0.25). Regarding CPD, having 
AMI was associated with an 40.5% increase in CPD compared to those without AMI (ß=0.34, 95% CI: 0.12, 
0.57), and for total consumption, having AMI and receiving any treatment was associated with a 43.3% increase 
in total consumption (ß=0.37, 95% CI: 0.12, 0.60). These estimates contradict our hypothesis that treatment 
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would ameliorate symptoms and therefore reduce the magnitude of the coefficients for the ‘treated’ AMI 
participants relative to the ‘untreated’ participants with AMI. Regarding sociodemographic variation, in this set 
of cross-sectional models where we were able to include time-invariant characteristics, women were less likely 
to smoke, to smoke fewer CPD, and have lower total consumption than men. Nearly universally, Black or 
African American and Hispanic participants smoked at lower rates and consumed fewer cigarettes than 
Caucasian participants, and higher education was associated with reduced smoking, a relationship for which the 
magnitude of the association grew stronger with increased educational attainment.  
Discussion 
 
 Despite significant progress on reducing smoking rates among U.S. youth and adults,3,29 these benefits 
vary widely across sociodemographic subgroups of smokers.2,29 One group of adults that smokes at particularly 
high rates is adults suffering from symptoms of any mental illness, a condition that affects 1 in 5 adults 
annually.63 In order to investigate whether this disparity might be explained, in part, by variation in response to 
state-level smoking prevention policies over time, we conducted a longitudinal study of young adults who 
participated in the National Longitudinal Survey of Youth 1997 cohort, modelling associations between AMI, 
tobacco policy, and smoking outcomes and the role of treatment for AMI in potentially ameliorating these 
effects. Strengths of the study include the large pool of participants with available data across five time periods 
to rely upon for our models, the availability of the MHI-5 to capture young adults with symptoms of AMI 
without relying on self-reported previous diagnosis of AMI, and a modelling approach that controlled for time-
invariant heterogeneity across individuals. 
 Our findings regarding the significant and positive association between having AMI and all measured 
smoking outcomes are consistent with previous research, as those with AMI have been found to smoke at higher 
rates, to consume more cigarettes, and to have higher nicotine dependence.21,66,68 However, our sensitivity 
analysis of AMI classification revealed that how AMI is defined can significantly impact our perspective on this 
relationship. Minimizing the misclassification rate suggests that a score of 60 is the appropriate threshold for 
determining AMI (scores<60 indicate likely AMI), also most frequently cited as the clinically-relevant cutoff 
based on scoring guidelines,90 whereas the Minimax and prevalence matching methods suggest 68 is the 
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appropriate threshold.91 Finally, using the Youden Index and 0,1 method both yield a suggested threshold of 
76.91 Results of our sensitivity analysis revealed that smoking participation was robust to variation in the 
threshold for determining AMI status (Appendix 1-A), however we observed variation in statistical significance 
of AMI in its association with smoking behavior. Number of days smoking cigarettes was robust to raising the 
threshold to 68 (including more participants in the AMI group), however using a cutoff score of 76 rendered 
main findings statistically insignificant based on a 95% confidence interval. For both CPD and total 
consumption, raising the threshold from 60 to either 68 or 76 rendered the association between AMI and 
smoking behavior statistically insignificant. A conservative threshold requiring greater frequency of 
experiencing symptoms for classification as having AMI revealed that AMI was significantly associated with all 
smoking outcomes. The least conservative threshold allowed the greatest number of participants to be assigned 
as having AMI, reducing the magnitude and significance of these associations. While the strength of the MHI-5 
tool is its ability to capture likely AMI even among those who may not have received a diagnosis or treatment, 
further work in this area should explore opportunities to leverage the power of nationally-representative 
longitudinal data offering mental health information that may offer greater clinical relevance and data regarding 
symptom acuity. 
 The lack of statistical significance for our estimates for associations between price, tobacco control 
policies, and smoking outcomes in our saturated models (with the exception of  number of days smoking) seems 
counterintuitive in light of a wealth of previous evidence on this topic, in a variety of settings.29,58,87–89,98 There 
are a number of possible explanations for this result, the first related to the specification of price in our 
particular modelling approach. We employed person-level fixed effects in our models to control for 
unobservable and time-invariant heterogeneity among our study participants, however this requires models to 
only use information from participants for whom excise tax rate varied within their state of residence over time, 
or who relocated to a state with a higher or lower rate. As evidenced by the findings of a previous longitudinal 
study looking at similar outcomes among smokers in California,99 it could be that the frequency and magnitude 
of changes to excise tax rates within individual states across time, particularly after being adjusted to reflect real 
rather than nominal changes, were not large enough to reveal significant effects of excise tax rate on smoking 
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behavior.  This factor may also be true of our findings regarding lack of statistically significant associations 
between other tobacco control policies and smoking behaviors, as such policies may not change dramatically 
within states over the time horizon for our study, though we observe shifts in the strength of tobacco control 
initiatives across states. One way that other studies have circumvented this particular issue is by employing 
average price per pack of cigarettes as the primary price metric, as this value varies more widely across locality 
and over time.53,56 We tested the sensitivity of our models to use of real average cost per pack of cigarettes 
during the study time horizon, and found that doing so rendered the association between AMI and smoking 
participation no longer statistically significant, and increased the magnitude and significance of the interaction 
between AMI and price, in congruence with our original hypothesis (see Appendix 1-C). In addition, using cost 
per pack as our price measure also increased the magnitude of the significant, negative association between 
price and number of days smoking, and the magnitude of the significant, positive association between AMI and 
number of days smoking. We also observed that the coefficients for AMI in our CPD and total consumption 
models became both negative, quite small in magnitude, and statistically insignificant. While average cost per 
pack has an advantage over excise tax in our models in terms of the magnitude of variation over time, tobacco 
companies have been able to respond to increases in tax rates by passing price increases on to consumers and 
concurrently raising per-pack prices in high consumption areas to offset a decline in overall demand,76 while 
also offering purchase price incentives such as coupons,100 making average cost per pack an imprecise measure 
subject to market forces,76 reducing the usefulness of our estimates to inform policy as easily as findings 
regarding excise tax rates. 
 A final thought regarding the role of price and other policies in determining our outcomes relates to the 
addictive nature of nicotine contained in cigarettes. Our current models do not account for the influence of 
addiction on future smoking behavior, however other investigators have pointed out that this can significantly 
impact smoking despite rising prices and increased strength of other tobacco prevention policies.89 
Incorporating measures representing cigarette use or level of consumption in the previous period represents a 
state of myopic addiction by allowing use behaviors in the current period to reflect the addictive nature of 
nicotine, predicting that use in a previous period will be both a positive and significant predictor of current 
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use.89 We tested this hypothesis using cross-sectional data from 2010, including a variable representing smoking 
behaviors in the 2008 period in our models. Results from this sensitivity analysis support those expectations, 
revealing that previous smoking behavior was positively associated with current use patterns (see Appendix 1-
D). Subsequent analyses of our participants sample revealed that the rate of smoking participation did indeed go 
down between 2002 and 2010 as participants grew older, and many gained both higher educational attainment 
and higher levels of income, all factors associated with reductions in overall cigarette smoking compared to 
youth and young adult experimentation and use.29 
 In addition, previous work has indicated that other factors such as parental and peer smoking or tobacco 
use may be some of the most significant predictors of initiating and continuing smoking during youth and 
young adulthood,101,102 factors for which we were unable to account in our current study. Future efforts in this 
area could explore the sensitivity of our estimates to use of the real, average price of cigarettes facing each 
participant rather than excise tax rate alone, to extending the survey period to potentially capture wider variation 
in excise tax rates, inclusion of variation in federal cigarette excise tax rates which would affect all participants, 
inclusion of municipal-level taxation data in real price calculations, and utilizing data offering insight into other 
highly significant predictors of tobacco use such as parental and peer influence..  
 Finally, our findings related to the role of treatment in predicting smoking outcomes present a different 
picture from what we hypothesized. Rather than pointing to an association between AMI and cigarette 
consumption of smaller magnitude for those who had experienced any treatment within the previous 12 months, 
our estimates suggest that those with AMI who participated in any treatment smoked more cigarettes per day 
and had higher total consumption than those without AMI. In addition, there were no statistically significant 
differences across treatment participation among smokers with AMI related to probability of smoking or 
measures of consumption. This finding could be due to selection into treatment, the fact that those who sought 
treatment had significantly more acute symptoms, and potentially smoked at higher rates already, which would 
be consistent with previous evidence describing the association between diagnosis category and variation in 
smoking rates.21,38,66,68 We also relied upon a small sample size of adults with AMI who had participated in any 
treatment (n~200), and did not have access to data regarding diagnosis, making it difficult to assess 
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representativeness of the sample or to generalize findings to the full population of adults with AMI. Finally, we 
investigated whether treatment for AMI was associated with variation in smoking behavior and found in a very 
limited sample that it was not. Despite this finding, a wealth of previous evidence has suggested that treatment 
for smoking cessation can be effective among this population if offered diagnosis-specific cessation 
support,67,68,103 offering  positive news regarding cessation potential among adults with AMI. Further work in 
this area could harness the power of large, nationally representative data sources offering AMI classification 
tools that do not require self-report of a diagnosis, but which offer increased ability to offer advanced 
classification in regard to severity of symptoms, treatment, and smoking behavior.  
Limitations 
 
Several limitations should be noted regarding the study. The first is that all data related to smoking behavior are 
self-reported. In addition, previous studies have noted that smoking may in fact impact experience and severity 
of symptoms of mental illness, therefore the direction of these associations bears further investigation. In terms 
of measurement of price and policy variables, municipalities share authority to levy additional taxes on cigarette 
sales, therefore state-level excise tax rates may not sufficiently capture the tax rate to which each participant 
would have been subject across location and time. Further, rising per-pack prices may fuel interest in obtaining 
cigarettes from a locality in close proximity that offers lower excise tax rates (‘smuggling’), or via online 
purchasing, a factor which has been shown to be associated with smoking behavior, but was not captured in our 
models.104 We also face a lack of advanced classification in the available mental health measure; an ideal 
measure would offer insight into how symptom severity for those with AMI may influence our outcomes.  
Conclusion 
 
 U.S. adults with AMI suffer disproportionately from the burden of tobacco-related morbidity and 
mortality, and effective public policy strategies tailored to help this group of smokers reduce or quit cigarette 
use remain elusive. Our results suggest that, while adults with AMI may be more likely to smoke and to have 
increased cigarette consumption, they do not appear to respond differently to price policies than adults without 
AMI. Our findings offer evidence that current popular tobacco prevention policies may be just as effective at 
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reducing smoking among this population, but therefore underscore the need to further investigate the role of 
mental health and tobacco cessation treatment alternatives tailored to the unique needs of adults suffering from 
the dual burdens of both AMI and chronic tobacco use. 
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Table 1-1. Weighted Descriptive Characteristics of NLSY 97 Participants in Study Period 1 (2002) 
(n=7,165) 
 Total Sample 
n= 7,165 
% (CI) 
Smoked Since Date of Last Interview  
   Yes 46.4 (44.8, 48.0) 
   No 53.6 (52.0, 55.2) 
Total Cigarette Consumption2 256.1 (6.85) 
Cigarettes Per Day2 9.3 (0.23) 
Number of Days Smoked2 19.1 (0.25) 
AMI Symptoms 17.41 (16.53, 18.30) 
   Yes 23.7 (22.7, 24.7) 
   No 76.3 (75.3, 77.3) 
State Cigarette Excise Tax Rate ($) 0.69 (0.02) 
Sex  
   Female 48.8 (47.4, 50.2) 
   Male 51.2 (49.8, 52.6) 
Age  
   18-20 59.7 (58.6, 60.7) 
   21-25 40.3 (39.3, 41.4) 
Race/ethnicity3  
   Caucasian 70.5 (68.4, 72.5) 
   Black or African American 15.5 (13.8, 17.2) 
   Hispanic 12.8 (11.5, 14.2) 
   Mixed Race 1.3 (0.9, 1.7) 
Education  
   No Degree 22.4 (21.3, 23.6) 
   HS Diploma or GED Equivalent 75.4 (74.2, 76.7) 
   Some College/Associate Degree 1.0 (0.8, 1.3) 
   Bachelor’s Degree 1.2 (0.9, 1.5) 
Annual HH Income  
   Less than $12,400 21.4 (19.3, 23.6) 
   $12,401-$37,499 23.4 (21.7, 25.3) 
   $37,500-$73,499 25.7 (24.1, 27.3) 
   $73,500+ 29.5 (27.5, 31.6) 
2All smoking behavior measures refer to past 30-day use among participants currently smoking; total cigarettes is a 
summary measure of consumption constructed by multiplying cigarettes per day and number of days smoked; 
weighted sample means and standard errors reported. 
3Categories assigned by NLSY97 investigators. 
 
 37 
Table 1-2. Associations between Variation in AMI Symptoms, Excise Tax, and Smoking Participation among NLSY97 Participants (2002-
2010) 
   Smoked Since 
Date of Last 
Interview1 
ß (95% CI) 
n=7,087 
  
AMI      
   No     Ref 
   Yes  0.03 (0.02, 0.04) 0.04 (0.02, 0.05) 0.04 (0.02, 0.05) 0.04 (0.02, 0.05) 
AMI * ln(State Excise Tax)   0.01 (-0.01, 0.01) 0.01 (-0.01, 0.02) 0.01 (-0.01, 0.02) 
ln(State Excise Tax)2 -0.02 (-0.03, -0.01) -0.02 (-0.03, -0.01) -0.02 (-0.03, -0.01) -0.02 (-0.03, -0.01) -0.01 (-0.01, 0.01) 
Tobacco Control Index    -0.01 (-0.01, 0.01) -0.01 (-0.01, 0.01) 
Age      
   18-20     Ref 
   21-25     0.01 (-0.01, 0.03) 
   26-30     -0.01 (-0.03, 0.02) 
Education      
   No Degree     Ref 
   HS Diploma/GED     -0.02 (-0.06, 0.02) 
   Some College/Assoc. 
Degree 
    -0.02 (-0.07, 0.03) 
   Bachelor’s Degree+     -0.03 (-0.08, 0.01) 
Annual HH Income      
   Less than $12,400     Ref 
   $12,401-$37,499     0.01 (-0.01, 0.02) 
   $37,500-$73,499     -0.01 (-0.02, 0.01) 
   $73,500+     0.01 (-0.01, 0.02) 
Year      
   2002     Ref 
   2004     -0.01 (-0.03, 0.01) 
   2006     -0.01 (-0.03, 0.01) 
   2008     -0.03 (-0.05, -0.01) 
   2010     -0.06 (-0.09, -0.03) 
Bolded p-values indicate statistical significance <0.05. 
1A fixed effects regression with heteroskedasticity-robust standard errors tested associations between smoking participation, AMI, and state tax rates 
over time.  
2State Excise Tax is the tax rate facing each participant during each survey period. 
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Table 1-3. Associations between Variation in AMI Symptoms, Excise Tax, and Total Cigarette 
Consumption among NLSY97 Participants (2002-2010) 
 Number of Days 
Smoked 
Cigarettes1,2 
ß (95% CI) 
n=2,599 
Cigarettes Per 
Day1,3 
ß (95% CI) 
n=2,555 
Total Cigarette 
Consumption1,4 
ß (95% CI) 
n=2,529 
AMI    
   No Ref Ref Ref 
   Yes 0.01 (-0.01, 0.03) 0.10 (0.06, 0.15) 0.11 (0.06, 0.16) 
AMI * State Excise Tax -0.01 (-0.03, 0.01) 0.01 (-0.04, 0.05) 0.01 (-0.04, 0.07) 
State Excise Tax5 -0.02 (-0.03, -0.01) -0.01 (-0.06, 0.03) -0.03 (-0.07, 0.02) 
Tobacco Control Index -0.01 (-0.02, 0.01) -0.01 (-0.03, 0.02) -0.01 (-0.03, 0.02) 
Age    
   18-20 Ref Ref Ref 
   21-25 0.03 (-0.01, 0.07) 0.05 (-0.03, 0.12) 0.07 (-0.02, 0.15) 
   26-30 0.01 (-0.04, 0.05) 0.03 (-0.07, 0.13) 0.05 (-0.06, 0.16) 
Education    
   No Degree Ref Ref Ref 
   HS Diploma or GED 
Equivalent 
0.04 (-0.02, 0.09) 0.01 (-0.10, 0.10) 0.03 (-0.08, 0.13) 
   Some College/Associate 
Degree 
0.01 (-0.09, 0.11) -0.01 (-0.16, 0.15) -0.01 (-0.19, 0.17) 
   Bachelor’s Degree+ 0.01 (-0.09, 0.09) -0.09 (-0.22, 0.05) -0.10 (-0.26, 0.05) 
Annual HH Income    
   Less than $12,400 Ref Ref Ref 
   $12,401-$37,499 -0.01 (-0.04, 0.01) 0.01 (-0.05, 0.06) 0.01 (-0.05, 0.07) 
   $37,500-$73,499 -0.02 (-0.04, 0.01) -0.02 (-0.08, 0.03) -0.02 (-0.08, 0.05) 
   $73,500+ -0.03 (-0.06, 0.01) -0.01 (-0.07, 0.05) -0.01 (-0.08, 0.06) 
Year    
   2002 Ref Ref Ref 
   2004 0.03 (-0.01, 0.05) -0.01 (-0.07, 0.05) 0.01 (-0.06, 0.07) 
   2006 0.02 (-0.02, 0.05) 0.02 (-0.05, 0.08) 0.02 (-0.05, 0.09) 
   2008 0.02 (-0.02 0.06) 0.03 (-0.05, 0.10) 0.03 (-0.05 0.12) 
   2010 0.04 (-0.01, 0.09) 0.01 (-0.08, 0.10) 0.02 (-0.08, 0.12) 
Bolded p-values indicate statistical significance <0.05. 
1Fixed effects Poisson regressions tested associations between cigarette consumption, AMI, and state tax rates 
over time. Coefficient represents the change in log value associated with each measure. 
2Number of days smoked refers to the number of days within the past 30-days a participant smoked cigarettes. 
3Cigarettes per day represents the average number of cigarettes smoked on days smoking in the past 30-days. 
4Total consumption in the past 30-days was constructed by multiplying the number of cigarettes smoked per day 
by the number of days a participant smoked cigarettes in the past 30 days. 
5State Excise Tax is the tax rate facing each participant during each survey period. 
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Table 1-4. Weighted Associations between Treatment for AMI Symptoms, Smoking Participation, and Cigarette Consumption among 
NLSY97 Participants, 2010 (n=6,918) 
 Smoking 
Participation 
ß (95% CI) 
n= 5,523 
 
Number of Days 
Smoked Cigarettes1,2 
ß (95% CI) 
n=1,803 
 
Cigarettes Per 
Day1,3 
ß (95% CI) 
n=1,803 
Total Cigarette 
Consumption1,4 
ß (95% CI) 
n=1,782 
AMI/Treatment     
   No AMI, No Treatment Ref Ref Ref Ref 
   Yes AMI, No Treatment 0.11* (0.08, 0.14) 0.03* (0.00, 0.11) 0.10 (-0.01, 0.20) 0.09 (-0.02, 0.20) 
   Yes AMI, Yes Treatment 0.15* (0.07, 0.23) 0.10* (0.04, 0.25) 0.34 (0.12, 0.57) 0.36 (0.12, 0.60) 
State Excise Tax5 -0.01 (-0.01, 0.02) 0.01 (-0.02, 0.04) -0.01 (-0.06, 0.03) -0.01 (-0.06, 0.04) 
Tobacco Control Index 0.01 (-0.01, 0.01) -0.01 (-0.03, 0.02) 0.01 (-0.04, 0.04) 0.01 (-0.04, 0.05) 
Sex     
   Male Ref Ref Ref Ref 
   Female -0.03 (-0.06, -0.01) 0.01 (-0.04, 0.06) -0.20 (-0.29, -0.10) -0.18 (-0.29, -0.07) 
Age     
   21-25 Ref Ref Ref Ref 
   26-30 -0.01 (-0.11, 0.09) -0.10 (-0.21, 0.02) 0.06 (-0.17, 0.30) 0.01 (-0.24, 0.27) 
Race/ethnicity3     
   Caucasian Ref Ref Ref Ref 
   Black or African American -0.14 (-0.18, -0.11) -0.12 (-0.18, -0.05) -0.47 (-0.58, -0.36) -0.54 (-0.66, -0.41) 
   Hispanic -0.17 (-0.20, -0.13) -0.25 (-0.34, -0.16) -0.62 (-0.79, -0.45) -0.73 (-0.91, -0.54) 
   Mixed Race 0.05 (-0.09, 0.19) 0.04 (-0.14, 0.22) -0.30 (-0.65, 0.04) -0.28 (-0.66, 0.10) 
Education     
   No Degree Ref Ref Ref Ref 
   HS Diploma or GED 
Equivalent 
-0.16 (-0.21, -0.12) -0.06 (-0.10, -0.02) -0.19 (-0.30, -0.08) -0.23 (-0.35, -0.10) 
   Some College/Associate 
Degree 
-0.32 (-0.38, -0.27) -0.09 (-0.19, 0.01) -0.34 (-0.59, -0.09) -0.42 (-0.70, -0.14) 
   Bachelor’s Degree+ -0.38 (-0.43, -0.34) -0.43 (-0.54, -0.31) -0.72 (-0.91, -0.54) -0.90 (-1.13, -0.67) 
Annual HH Income     
   Less than $12,400 Ref Ref Ref Ref 
   $12,401-$37,499 -0.02 (-0.07, 0.04) 0.04 (-0.03, 0.10) 0.01 (-0.23, 0.11) 0.03 (-0.11, 0.16) 
   $37,500-$73,499 -0.04 (-0.10, 0.01) 0.05 (-0.01, 0.11) -0.08 (-0.18, 0.03) -0.03 (-0.15, 0.10) 
   $73,500+ -0.07(-0.12, -0.01) -0.01 (-0.09, 0.06) -0.08 (-0.22, 0.05) -0.06 (-0.22, 0.10) 
Bolded p-values indicate statistical significance <0.05; *indicates that while both estimates are individually significant, an Adjusted Wald test 
revealed they were not significantly different from each other. 
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1A linear model with person-level fixed effects tested associations between treatment and smoking participation; Poisson regressions with 
heteroskedasticity-robust standard errors tested associations between cigarette consumption, AMI, and state tax rates over time.  
2Number of days smoked refers to the number of days within the past 30-days a participant smoked cigarettes. 
3Cigarettes per day represents the average number of cigarettes smoked on days smoking in the past 30-days. 
4Total consumption in the past 30-days was constructed by multiplying the number of cigarettes smoked per day by the number of days a participant 
smoked cigarettes in the past 30 days. 
5State Excise Tax is the tax rate facing each participant during each survey period.  
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Chapter 2 Investigating the Responsiveness of Adult Smokers with Mental 
Illness to Prospective Regulatory Strategies to Reduce Combustible Cigarette 
Use. 
 
Abstract 
 
Background: Overall use of potentially less harmful products such as e-cigarettes among adults remains 
significantly lower than combustible cigarette use (3.2% vs 13.7% in 2018), and combustible cigarette use and 
its associated health risks are remain stubbornly higher over time among some populations, such as adults with 
symptoms of any mental illness (AMI)d (28.1% in 2018). We still lack evidence regarding price elasticity of 
demand for cigarettes, and likelihood of substitution to potentially less harmful products among adults with 
AMI. 
Methods: 407 U.S. adult smokers were recruited to perform theoretical online cigarette purchase tasks to 
estimate difference in own-brand (OB) price elasticity of demand, and demand for alternative tobacco products 
among adults with AMI and those without. Linear regression models were fit to the data, modeling associations 
between AMI, price, and 1) variation in demand for own-brand cigarettes at different prices, 2) demand for four 
alternative products when the price of the own-brand product varied.  
Results: A 10% increase in OB price was significantly associated with an 8% reduction in OB demand across 
all participants (ß=-0.788, SE: 0.041, p<0.05), and the association an interaction between AMI and price was 
positive and significant (ß=0.133, SE: 0.600, p<0.05). OB price was a significant and positive predictor of 
increased demand for all products but the reduced harm e-cigarette, and AMI was only significant in predicting 
increased demand for an e-cigarette with equivalent nicotine to the OB cigarette. 
Conclusions:  Adults with AMI may be more reluctant to reduce smoking in the face of higher prices; however, 
they may be just as likely to choose substitutes under certain price and product policy conditions.  Further 
 
d AMI was defined as experiencing an emotional, behavioral, or mental disorder that met DSM-IV criteria; severe mental illness 
(SMI) classification includes that stipulation that the disorder ‘substantially interfered’ with at least ‘one major life activity.’ The AMI 
category does not include individuals with substance abuse or developmental disorders.63 
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research focusing on perceptions of and demand for various potentially less harmful products among this 
population could further illuminate a path to more effective policies related to alternative tobacco products.  
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Introduction 
  
 While combustible cigarette smoking recently reached its lowest recorded rate (13.7%) among U.S. 
adults,3 the market for tobacco products continues to expand, with smokers facing a wide array of nicotine-
containing product choices. The United States Food and Drug Administration (FDA) cites nine different classes 
of tobacco products available to consumers, with a tenth available as of April 2019.105,106 Included in this list are 
a category of alternative, non-combustible electronic nicotine delivery systems (ENDS) such as electronic (e-) 
cigarettes,105 use of which has been growing in popularity among youth and young adults.107,108 E-cigarettes 
heat a nicotine-containing liquid to produce an aerosol inhaled by the user, which some evidence suggests may 
prove less harmful to the user than inhaling chemicals produced through combustion when smoking 
conventional cigarettes.109,110 Despite substantial progress in reducing adults smoking rates and the availability 
of potentially less harmful alternative tobacco products, overall use of e-cigarettes among adults remains 
significantly lower than combustible cigarette use (3.2% vs 13.7% in 2018),3,111 and combustible cigarette use 
and its associated health risks are remain stubbornly higher over time among some populations, such as adults 
with symptoms of any mental illness (AMI)e (28.1% in 2018).18,21,63 The FDA is currently exploring several 
options to reduce combustible tobacco use, however the extent to which these strategies will be effective across 
subgroups of established smokers depends on the relative abuse liability of smokers’ preferred product and 
these alternative choices.23  
 Abuse liability refers to the likelihood of persistent use of a drug or product, including the likelihood of 
developing dependence or addiction, and experiencing adverse consequences from continued use.23 Nicotine is 
the primary addictive component of tobacco products, promoting continued use of once an individual begins 
using nicotine-containing products, though its abuse liability may vary depending on the attributes of the 
method it is delivered (inhaled by smoke produced through combustion in a conventional cigarette, or inhaled in 
e-cigarette aerosol, for example).23 Previous studies have found variation in abuse liability across nicotine 
 
e AMI was defined as experiencing an emotional, behavioral, or mental disorder that met DSM-IV criteria; severe mental illness (SMI) 
classification includes that stipulation that the disorder ‘substantially interfered’ with at least ‘one major life activity.’ The AMI 
category does not include individuals with substance abuse or developmental disorders.63 
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delivery alternatives,23 such as conventional and e-cigarettes,112–114 and across product characteristics (flavors) 
and potential regulatory scenarios (messaging about risks associated with use).115 One frequently used measure 
of abuse liability is the own-price elasticity of demand for a product, an index that reflects the relative value of 
cigarettes to the individual and how demand for cigarettes changes when they become more difficult to obtain 
(e.g., increase in price).113,116 A lower own-price elasticity of demand would therefore reflect higher abuse 
liability of cigarettes because it would signify that the participant is less willing to forego their own product 
even in the face of increasing prices.116 Abuse liability can also be compared across cigarettes and alternative 
tobacco product choices that are garnering interest from federal regulators for their potential to reduce the harm 
of combustible tobacco products (e.g., electronic cigarettes, low-nicotine cigarettes)117,118 by estimating a cross-
price elasticity of demand. While it remains difficult to observe smokers as they make choices between products 
offered at different prices in a real-world setting, simulated purchase tasks offer researchers alternative tools to 
assess abuse liability,23 and to compare abuse liability across products and among sub-groups of participants. 
 Adults with AMI smoke at significantly higher rates than those without these symptoms, smoke more 
cigarettes, report higher dependence on nicotine, and may have greater difficulty achieving cessation when they 
attempt to quit smoking.5,21,25,35,66,67 They also suffer at greater rates than the general population from tobacco-
related premature morbidity and mortality, making them a priority population for reducing disparities in adult 
smoking.68 Adults with AMI may use cigarette smoking as a tool to cope with symptoms of mental 
illness,45,68,69 thus experiencing greater difficulty reducing or ceasing use, despite evidence that this behavior 
may in fact exacerbate symptoms.68 If smokers with AMI have a stronger preference for their own-brand 
product and maintaining consumption than those without these symptoms, they will be less responsive to 
increases in price, thus less likely to reduce smoking as prices increase, and less willing to switch to a 
potentially less harmful and/or less expensive alternative product, limiting the efficacy of tobacco prevention 
and control policies aimed at reducing the public health burden of tobacco.   
 Previous investigation focused on price elasticity of demand among smokers with AMI is limited. One 
landmark study in this area found that adults with AMI may be as responsive to price increases as those without 
AMI,74 other studies have focused on youth, and provide conflicting evidence that youth with symptoms of 
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AMI may be just as price elastic in their demand as youth without,80 but that youth experiencing symptoms such 
as suicidality may have less elastic demand.48 Recent work in this area has focused primarily on emerging 
tobacco products such as e-cigarettes, and suggests that adult smokers may be willing to substitute cigarettes for 
electronic cigarette liquid (e-liquid), that e-cigarettes may serve as a substitute for cigarettes at certain prices, 
and that e-cigarettes may have lower abuse liability than combustible cigarettes.113–115,119 Our review of the 
literature has only identified one published, lab-based study that has specifically included adults with AMI in 
the study sample.120 Results suggested that adults with AMI may be as likely as those without AMI to choose 
low-nicotine cigarettes under certain price conditions, however the sample size for the study was small (n=56), 
and comparison groups were opioid dependent participants and socioeconomically disadvantaged women, 
rather than comparing results to adults without AMI symptoms. No studies to date have examined the 
relationship between demand for cigarettes and e-cigarettes among smokers with and without AMI, which is 
particularly important as policymakers try to regulate non-combustible tobacco products, like e-cigarettes, to 
reduce combustible product use among population group that use combustible products at high rates. 
 The FDA is currently exploring two options to reduce combustible tobacco use: reducing nicotine levels 
in cigarettes to non-addictive levels, and evaluating the use of e-cigarettes as a lower harm alternative (see 
Appendix 2-A).16,17 An additional policy tool is the regulatory power to grant permission for use of advertising 
language suggesting a product (such as an e-cigarette) reduces exposure to a substance or that it poses less 
harm, if a Modified Risk Tobacco Product (MRTP) Application is approved (none have yet been approved).121 
FDA will not benefit from longitudinal data about the likely effects of these policy alternatives for smokers with 
AMI for years to come, however strategies such as the CPT allow researchers to model hypothetical purchasing 
behavior that is highly correlated with real world purchasing.122,123 Doing so creates an opportunity to offer 
insight into whether FDA regulatory strategies under consideration are likely to induce the desired behavior 
among adult smokers, and if smokers with and without AMI are equally likely to benefit.  
 To address a gap in knowledge regarding the abuse liability of different products among smokers with 
AMI, this study will test for differences in hypothetical demand for cigarettes and substitution to potentially 
lower harm alternative tobacco products between adult smokers with and without AMI, under several potential 
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policy conditions - using survey data collected online from 407 survey participants via Amazon’s Mechanical 
Turk. Policy scenarios include 1) the option to have a combustible cigarette with half the amount of nicotine as 
their own brand choice, 2) an e-cigarette with the same amount of nicotine as their own-brand cigarette, 3) an e-
cigarette with a reduced harm message, and 4) an e-cigarette with a reduced exposure message. 
Conceptual Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
  
 The conceptual model from Figure 3 describes expectations regarding the role of mental illness, and 
nicotine dependence in shaping preferences about consumption of a smoker’s own-brand product, and the 
relative value of alternative products. In order to maximize their well-being (utility) smokers weigh the costs 
and benefits of purchasing these products, and shape preferences regarding their willingness to pay (WTP) to 
consume their own product or an alternative product. WTP can be observed through theoretical purchasing 
behavior, and the conceptual model illustrates a hypothesis that smokers with AMI may have higher 
dependence on their own product, as consumption maximizes their utility and maintains their addictive stock, 
and also may believe that smoking helps them reduce symptoms of AMI such as negative affect. If smokers 
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with AMI have a stronger preference for their own-brand product and maintaining consumption, they will be 
less responsive to increases in price (have lower price elasticity of demand), thus less willing to switch to a 
potentially less harmful and/or less expensive alternative product.  
Hypotheses 
 
H2: AMI will moderate the association between price and demand. 
H2a) Adult smokers with AMI will be less sensitive to price increases of their own brand cigarette and,  
H2b) more reluctant to switch to a potentially less harmful alternative when the price of their own-brand 
product increases.  
Methods 
 
Sample 
 
 A convenience-sourced sample of 407 adult smokers was recruited via Amazon’s Mechanical Turk 
(MTurk) to participate in the study (201 smokers with AMI symptoms and 206 without) between April 21,2020 
and June 6, 2020.  3,854 MTurk users were screened to obtain the sample of 407 study participants. Each 
participant was asked to complete assessments of AMI and cigarette purchase tasks (CPT) that were used to 
estimate the abuse liability of cigarettes for their own brand product alone and in comparison to four alternative 
tobacco products (see above).  
Screening Participants for Eligibility 
  Adult users of the MTurk platform with a U.S. IP address were invited to complete a short, five 
question screener survey via Qualtrics to see if they qualified for the study, with the goal of enrolling 200 
smokers with AMI and 200 smokers with no AMI symptoms (see Appendix 2-B for screener questions). A goal 
of 200 participants per group was obtained by performing a power analysis using information about mean price 
elasticity of demand across multiple studies,89 compared to that statistic from the limited number of studies that 
have focused on demand among participants with AMI.48,80 Non-institutionalized, U.S. adults (ages 18+) who 
currently smoked every day or some days (within the previous week) and who had smoked at least 100 
cigarettes in his/her lifetime were eligible to participate in the full survey. In order to populate the study sample 
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with smokers with and without AMI, we included two screening questions from the Patient Health 
Questionnaire (PHQ)-2, a two-item scale asking participants how frequently over the past two weeks they have 
been bothered by “feeling down, depressed, or hopeless” and experienced “little interest or pleasure in doing 
things.” Response options include a range from “not at all” (score of zero) to “every day” (score of three), with 
a total score of three or higher representing a reliable and validated threshold for assessing likely 
depression.124,125 Interested participants completed the eligibility screener and received $0.50 for successful 
completion. We employed a quota system to deem eligible the first 200 smokers without PHQ-2 scores above 
three (smokers without AMI), and to deem eligible the first 200 smokers with scores of three or above on the 
two-question mental illness assessment (likely AMI).  
Eligible participants were then randomized at the end of the screener to receive a link in Qualtrics to one of 
eight versions of the full survey to complete in REDCap , each of the eight versions varied the order with which 
participants completed the cross-product tasks; they always completed the own-brand CPT first. Completion of 
the survey offered them a code redeemable for $2.00 via MTurk. This level of compensation is greater than or 
commensurate with compensation levels for other MTurk surveys; the effect of varying levels of compensation 
on survey participation has been evaluated to impact speed of recruiting participants rather than compromising 
quality of data in any way.126,127 Previous research has indicated that MTurk yields participant pools that may be 
equally as diverse as traditionally-recruited samples, despite the tendency for participants to be slightly younger 
and more educated than traditional samples.127–129 3,854 interested MTurk workers completed the screener, 
yielding 623 eligible participants, 420 of whom completed the survey, of which 407 correctly answered a 
mandatory attention check question to be retained into the final sample. 
Cigarette Purchase Task Measures 
 
 Each participant was asked to complete five total cigarette purchase tasks, hypothetical tasks highly-
correlated with real-world behavior.122 The first task asked participants how many times they would buy 10 
puffs of their own-brand cigarette at sixteen different prices ($0.00-$10.24). The remaining four CPTs were 
cross-product tasks that asked participants how many times they would buy 10 puffs of their own-brand 
cigarette and 10 puffs of an alternative product if both were available, while the price of their own-brand 
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product varied (16 alternatives, $0.00-$10.24) and the cost of the alternative product stayed fixed at $1.00 (see 
Appendices 2-C and 2-D). Cross-product condition choices included availability of 1) a cigarette with half the 
amount of nicotine as their own-brand product, 2) an e-cigarette with the same amount of nicotine as their own-
brand cigarette, 3) an e-cigarette “that reduces your risk of developing cancer or heart disease compared to 
your own brand cigarette” (reduced harm condition), 4) an e-cigarette “that exposes you to fewer toxicants that 
cause cancer compared to your own brand  cigarette” (reduced exposure condition). 
  The primary outcomes of interest are differences in own-brand price elasticity of demand, and in cross-
price elasticities of demand, for individuals with and without AMI, and interactions between AMI and price. 
Own-brand price elasticity of demand is reported as the percent change in reported consumption associated with 
a 10% increase in price.46,89 Cross-product elasticity estimates represent the percent change in consumption of 
the alternative product associated with a 10% increase in own-brand product price. Consumption and price were 
log-transformed to provide elasticity estimates.89 Secondary own-brand product demand measures of interest 
include: 1) Intensity (the level of consumption when price equals $0.00), 2) Breakpoint (the first price at which 
cigarette consumption equals zero), 3) Omax (the maximum amount spent on cigarettes), and 4) Pmax (the price at 
which participants maximized their expenditure).122,130 Intensity, Omax, and Pmax were also transformed using a 
natural log transformation, based on the distribution of participant responses. 
 Two data quality checks were conducted to exclude participant data if responses to hypothetical 
purchasing indicated significant or systematic deviation from typical trends: participant data was excluded if 
responses reported a trend of increasing consumption as price increased (potentially indicating a participant did 
not understand the task), or if a participant exhibited ‘reversal from zero’.131 Reversal from zero would occur if 
a participant chose to consume zero puffs at two consecutive prices, and then reversed course at a higher price 
to choose to consume again.131 12 participants were excluded from analyses based on these quality check 
measures.  
Any Mental Illness Measures 
 
 Depression was used in this study as the primary symptom measure of AMI, as it is one of the most 
prevalent mental illnesses experienced by U.S. adults,132 and in 2016 alone, approximately 6.7% of all U.S. 
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adults were estimated to have experienced a major depressive episode within the previous year.133 The Patient 
Health Questionnaire 9-Item Scale (PHQ-9) assessed likely AMI among enrolled study participants. 
Participants were asked to rate how frequently they have experienced nine different symptoms of depression 
within the previous week, with response options ranging from “Not at all” (0) to “Nearly every day” (3). A total 
score was obtained by adding the response values across questions (range: 0, 27). The PHQ-9 is a validated 
measure of depression, with a clinically-relevant threshold of scores greater than or equal to 10 indicating 
moderate to severe depression, with a sensitivity and specificity of 88% at this threshold.132,134,135 A meta-
analysis of PHQ-9 alternative thresholds found no significant differences for use of scores between 8 and 11 for 
depression classification.135  In order to account for unusual circumstances during data collection, we also asked 
participants to repeat the PHQ-9 but instead we asked about how frequently they experienced the symptoms 
above within the previous 12 months.f We used this measure in sensitivity analyses to account for potential bias 
due to unusual circumstances. 
Nicotine Dependence and Tobacco Use Measures 
 
 Nicotine Dependence: Nicotine dependence is significantly associated with real-world smoking 
behavior, therefore we asked participants to rate their dependence on cigarettes, using 12 items from the 
primary and secondary dependence motives scales from the Wisconsin Inventory of Smoking Dependence 
Motives (WISDM).136 Participants received an average score (range: 1-5), with higher average scores indicating 
higher dependence.  
 Weekly Spending on Cigarettes: Weekly spending on cigarettes offers insight into how much financial 
investment each participant makes in tobacco use per week, an important distinction from frequently included 
financial covariates such as household income, as it offers insight into the relative value of cigarettes to each 
participant, and potentially the likelihood of reporting continuing spending at price higher levels in the purchase 
 
f Data collection was launched in late April 2020, approximately one month after the novel coronavirus 2019 (Covid-19) pandemic 
forced nationwide implementation of state by state stay at home or shelter in place orders. During this period, the proportion of U.S. 
adults reporting symptoms of anxiety and depression was significantly higher than normal,146 and stress and anxiety related to the 
pandemic could be exacerbated among some populations, such as those with AMI.183 
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tasks. Spending categories were created based on distribution of responses (Less than $10, $10-$24, $25-$49, 
$50-$150). 
Smoking Motivation, Peer and Family Effects Measures 
 We included additional variables in our model to validate our assumptions and to control for factors 
influencing both smoking behavior and experience of AMI. To validate the assumption underlying our 
hypothesis, that participants with AMI will find it more difficult to forego consumption as the price of their 
preferred product increases, due to use of smoking as a coping tool,45,68 we asked participants whether they 
agreed with the following statement from the “Why Do You Smoke?” self-assessment questionnaire: “When I 
feel blue or want to take my mind off  cares and worries, I smoke cigarettes” (Yes/No).137 We also asked 
participants to rate the perception of tobacco use by people who were important to them (ordinal scale with 
Negative/Very Negative grouped together in contrast with Positive/Very Positive),138 as peer and family 
tobacco use significantly influences use behaviors starting at a young age and continuing into adulthood.37,85,102 
To control for factors associated with both experiencing AMI and substance use,139,140 we also asked 
participants whether a biological parent or sibling had ever been diagnosed with anxiety, depression, or any 
other psychiatric illness (Yes/No). 
Demographic Covariates 
 
 Covariates also associated with tobacco use behaviors included sex (Male/Female), age (18-24, 25-34, 
35-44, 45-54, 55+), race/ethnicity (White non-Hispanic, Black or African American non-Hispanic, Asian, 
Hispanic or Latino, or Other) educational attainment (HS/GED or less, Some College, Bachelors’ degree or 
higher), and annual income (Less than $10,000, $10,000-$24,999, $25,000-$49,999, $50,000-$99,999, 
$100,00+).27,141 
Statistical Analysis 
   
 Characteristics of the study sample were described using univariate statistics, and Pearson’s chi-square 
tests and t-tests were used to provide bivariate statistics describing significant between-group differences across 
AMI status. Linear regressions with standard errors clustered at the individual level were used to estimate 
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relationships between consumption and own-brand (OB) price elasticity of demand based on variation in self-
reported consumption at the sixteen different price points offered for own-brand cigarettes (see Appendix 2-C), 
AMI, an interaction between AMI and price elasticity, and covariates described above. A similar model was 
used for the cross-purchase tasks, however the consumption variable represented consumption of the alternative 
product as the price of the OB product varied (see Appendix 2-D). Linear regressions with standard errors 
clustered at the individual level estimated the associations between four secondary outcomes (Intensity, 
Breakpoint, Omax, Pmax), AMI, and covariates. Primary models were estimated as follows: 
OB Price Elasticity of Demand 
1) lnConsumptionOB = + ßlnPriceOB + ηAMI + λAMI  lnPriceOB + XiΩ + εi 
Cross Product Price Elasticity of Demand 
2) lnConsumptionAlternative =  + ßlnPriceOB + ηAMI + λAMI  lnPriceOB + XiΩ + εi 
Where η  and λ are the parameters of interest to be estimated, and additional covariates include individual level 
demographic controls, nicotine dependence and tobacco spending, smoking motivation, and peer and family 
effects.  
If AMI moderates the relationship between price and consumption as hypothesized, λ will be both 
positive and significant in the OB task, and negative and statistically significant in the cross-product tasks. 
Secondary Outcomes 
3) Intensity/Breakpoint/Omax/Pmax=  ηAMI + XiΩ + εi 
Models were estimated and are reported progressively, from a simple regression of consumption on price, 
AMI, and an interaction between AMI and price, to a fully saturated model with all covariates, in order to 
describe relevant changes to coefficients of interest as additional factors were accounted for in our models. All 
analyses were performed using Stata 16 (College Station, TX). 
 
Results 
 
Sample Description and Unadjusted Associations between AMI Status and Participant Characteristics 
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 Our study sample of smokers was predominantly male (68.1%), ages 25-44 (77.3%), identified as Non-
Hispanic Caucasian (49.6%), with a Bachelors’ degree or higher (66%), and reported earning between $25,000 
and $100,00 per year (57.8%) (Table 2-1). The average nicotine dependence score was 2.8 (range: 1-5), with 
most participants reporting that people close to them had a negative or very negative opinion about tobacco use 
(79.6%). Weekly spending on cigarettes was approximately evenly split across categories, with just slightly 
more participants than not reporting smoking to cope with negative feelings (53.1%) and having a family 
history of AMI (53.3%). We observed significant between group differences across a number of characteristics, 
with those classified as having AMI more likely to be younger (73.1% under the age of 35, versus 52% of those 
without AMI, p<0.01), less likely to identify as Non-Hispanic Caucasian (42.8% vs. 56.3% for those without 
AMI, p<0.01), and more likely to identify as Hispanic (22.9% of those with AMI vs. 9.2% of those without, 
p<0.01) or “Other” (4.0% vs. 1.9% for those without AMI, p<0.01). Adults with AMI were also more likely to 
report earning less than $50,000 per year (71.7% vss. 50% of those without AMI, p<0.01). Adults with AMI 
reported higher average nicotine dependence scores than those without AMI (3.04 vs. 2.56 respectively, 
p<0.01), were more likely to report smoking to cope with feelings of worry or sadness (53.2%) than those 
without AMI (40.8%, p<0.05), to report that people important to them perceived tobacco use to be positive or 
very positive (29.1% of those with AMI vs. 10.5% of those without, p<0.01), and that a biological family 
member had been diagnosed with AMI (64.4% vs. 29.1% of those without AMI, p<0.01). 
Price Elasticity of Demand for Own Brand Cigarettes 
 
 Estimating the price elasticity of demand for OB cigarettes using solely AMI, price, and an interaction 
between price and AMI as regressors revealed that across participants, a 10% increase in price of OB cigarettes 
was significantly associated with an 8% reduction in demand for OB cigarettes (ß=-0.796, SE: 0.035, p<0.05), 
and having AMI was associated with a 146% increase in demand (ß=0.901, SE: 0.249, p<0.05) 
(100(exp(0.901)-1)=146) (Table 2-2, Rows 1a-1c). The interaction between AMI and price was positive and 
significant, revealing that AMI may moderate the association between price and demand and that adults with 
AMI may have less elastic demand despite rising prices (ß=0.198, SE: 0.051, p<0.05). Adding demographic 
covariates to the model produced similar results (Table 2-2, Rows 2a-2c), though the magnitude of the 
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coefficients for AMI, price, and the interaction term slightly decreased in magnitude (interaction: (ß=0.193, SE: 
0.051, p<0.05). Including measures of nicotine dependence and current demand (weekly spending) reduces the 
magnitude of the coefficient for price (ß=-0.717, SE: 0.026, p<0.05), and renders the association between AMI 
and demand no longer statistically significant, though the interaction between AMI and price remains both 
significant and positive (ß=0.163, SE: 0.052, p<0.05). Finally, including all covariates in previous models and 
adding indicators for smoking to cope and peer and family effects revealed in a fully saturated model that a 10% 
increase in price remained significantly associated with an 8% reduction in demand across all participants (ß=-
0.788, SE: 0.041, p<0.05), the association between AMI and demand became negative but not statistically 
significant, and the interaction between AMI and price remained positive and significant (ß=0.133, SE: 0.600, 
p<0.05). 
Cross Product Price Elasticities of Demand 
 
 Patterns were not uniform across alternative products. In initial models including only AMI, price, and 
the interaction term, positive and significant associations between OB price and demand for three out of four 
products was observed (Table 2-3, Rows 5a-5c). A positive and significant coefficient indicates that the 
alternative product functions as a substitute for OB cigarettes,113 thus a 10% increase in OB cigarette price was 
associated with a 1.06% increase in demand for a low nicotine combustible cigarette (ß=0.106, SE: 0.042, 
p<0.05), a 1.19% increase for an e-cigarette with the same level of nicotine (ß=0.119, SE: 0.039, p<0.05), and a 
0.63% increase in demand for an e-cigarette with a reduced harm message (ß=0.063, SE: 0.031, p<0.05). Across 
all four conditions, demand was also positive and significant for those experiencing AMI. For those with AMI, 
demand for a low nicotine combustible cigarette was nearly five times higher than it was for those without AMI 
(ß=1.598, SE: 0.335, p<0.05) (exp(1.598)=4.9), and demand for an e-cigarette with the same amount of nicotine 
as their OB cigarette approximately 7.4 times higher (ß=2.004, SE: 0.345, p<0.05). The interaction between 
AMI and price was positive but not significant for all products with the exception of the e-cigarette with 
equivalent nicotine, where it was both negative and significant, representing more reluctance to substitute to this 
alternative product as OB prices rose, consistent with our hypothesis Hb (ß=-0.025, SE: 0.050, p<0.05). When 
we controlled for demographic variables (Rows 6a-6c), price remained significant and positive for all but the 
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reduced exposure condition e-cigarette, and AMI remained both positive and significant. Including 
demographic variables rendered the interaction term no longer significant in the reduced harm condition. 
Adding indicators of dependence and weekly spending on cigarettes rendered AMI no longer a significant 
predictor of variation in demand for the low nicotine cigarette (Rows 7a-7c), and in the fully saturated models 
we observed that price was a significant and positive predictor of increased demand for all but the reduced harm 
e-cigarette (Rows 8a-8c), and AMI was only significant in predicting increased demand for the e-cigarette with 
equivalent nicotine to the OB cigarette. 
 Our final set of models predicted associations between secondary measures of OB cigarette abuse 
liability and AMI status, where the outcomes are natural log of intensity, Omax, and Pmax, and Breakpoint 
measured in dollars. Having AMI was associated with having a higher Breakpoint (price at which consumption 
reached zero), with a coefficient representing a Breakpoint on average $1.31 higher for those with AMI than 
those without (ß=1.31, SE: 0.40, p<0.05). Having AMI was associated with an Omax (maximum level of 
expenditure) nearly twice as high than that of participants without AMI (ß=0.63, SE: 0.19, p<0.05) (exp(0.63)= 
1.9), aligning with our hypotheses.  This trend was consistent when demographic controls were introduced, 
though the magnitude of those relationships was reduced. The parameter for the dependent variable Pmax was 
also positive though not significant, until we introduced measures of dependence and weekly spending, which 
rendered that association negative, and then statistically significant in the fully-saturated model, representing an 
average price at which spending was maximized more than one-third lower for those with AMI compared to 
participants without AMI (ß=-0.46, SE: 0.20, p<0.05). Intensity was uniformly lower for those with AMI, 
though not significant at p<0.05, and Breakpoint and Omax also changed signs in our fully saturated model to 
represent lower spending when we included family history of AMI and peer perceptions of tobacco use in our 
models. 
Discussion 
 
 This study addresses a significant gap in our knowledge regarding tobacco use among a population of 
smokers who smoke at higher rates than the general population of U.S. adults,5,21,67,68 tend to smoke more 
cigarettes63,142 and be more dependent on nicotine,5 and may have additional difficulty reducing or quitting 
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smoking.21 We investigated whether AMI may moderate associations between price policies and demand for 
cigarettes, and if it may moderate responsiveness of adult smokers to availability of alternative products 
representing different potential regulatory scenarios16,121,143 FDA may pursue to reduce the public health harms 
associated with combustible tobacco cigarettes. We found that smokers with AMI may have less elastic demand 
for cigarettes in the face of rising prices, and that though they are willing to substitute alternative products when 
cigarettes prices are raised, the extent to which they are willing to do so, and whether they do so at rates 
different from those without AMI depends on a variety of factors. A particular strength of our study is our use 
of a classification strategy for AMI that does not rely on previous diagnosis, expanding our ability to provide 
evidence that may offer more generalizable conclusions. 
   Characteristics of our study sample and associations between AMI and use behaviors are congruent 
with previous investigations in this area that have found smokers with AMI to have higher nicotine dependence 
than those without,5  and the importance of the role peer and family perceptions of tobacco use play in 
influencing use.37,102 We were also able to confirm our prediction based on previous work in this area,45,68 that 
smokers with AMI may smoke in part to ‘reduce negative affect,’ or undesirable mood symptoms, and that 
family history of AMI is significantly associated with current classification of having AMI as well.139 Including 
these factors in our models helps illustrate how significantly these factors may influence demand for cigarettes. 
When we controlled for AMI and demographic covariates alone (Table 2-2, rows 2a-2c), we observed higher 
OB demand among those with AMI symptoms, however including additional measures correlated with AMI 
and demand, such as nicotine dependence and weekly spending on cigarettes, led to our observation that AMI 
alone was no longer a significant predictor of higher demand and the magnitude of the coefficient was 
significantly reduced. Including information about peer perception of tobacco use, or of family history of AMI 
resulted in a negative association between AMI and OB demand, suggesting that these were strong and positive 
factors correlated with demand for tobacco. Findings from our investigation of secondary demand measures 
such as Breakpoint and Omax also supported this conclusion, as those with AMI exhibited higher willingness to 
spend and maximum spending until we introduced controls for these factors. However, the coefficient on the 
interaction between AMI and price remained statistically significant and positive in our main OB demand 
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model, indicating that AMI may indeed moderate the relationship between price and demand such that those 
with AMI are more reluctant to reduce smoking as price increases. To our knowledge, this is the first study to 
investigate this relationship as a moderating one and to confirm that hypothesis. Doing so indicates that 
policymakers should consider whether price policies are equitable in their ability to reduce smoking among 
high-risk populations. 
 Conclusions regarding demand for alternative products present a less cohesive story, as we found that 
different product conditions exhibited fairly different outcomes, which is intuitive on some level given the level 
of variation between alternatives presented. In congruence with a limited number of previous studies assessing 
substitutability of OB cigarettes with low-nicotine cigarettes,120,144 increased price was associated with positive 
demand for the low-nicotine cigarette. AMI was no longer a significant predictor of this relationship once we 
included covariates such as dependence and weekly spending on cigarettes, which builds upon knowledge 
gained from previous studies in a general population of adults to suggest that willingness to substitute may also 
be highly dependent on factors such as beliefs about whether low-nicotine cigarettes pose less harm,145 and 
whether a higher nicotine substitute is available.144 If FDA were to mandate lower levels of nicotine in 
combustible products, or increase taxes on cigarettes at nicotine levels present today, these results present 
tentative evidence that smokers, even those with AMI, may be willing to switch to a product with lower abuse 
liability. An e-cigarette with the same level of nicotine as the OB cigarette was more uniformly appealing, and 
those with AMI exhibited a strong positive response, though an interaction between AMI and price revealed 
that, under certain circumstances, those with AMI may prove more reluctant to switch to this alternative. A 
reduced harm e-cigarette garnered positive substitution rates, suggesting that, as found in previous studies, 
pairing of product type and risk message may significantly influence cross-price elasticity of demand.130 
However, in the fully saturated model, the effects were no longer statistically significant. Finally, those with 
AMI generally responded positively to the availability of a reduced exposure product, suggesting that there may 
be specific impact related to harm communication wording that those with AMI find meaningful. This bears 
further investigation as FDA must decide what modified risk messaging they may allow tobacco product 
manufacturers to employ in advertising if MRTP applications are approved. 
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 Finally, we performed this study among a sample of users experiencing an extraordinary pandemic 
event, with the potential to increase both reports of AMI among those who do not typically experience these 
symptoms,146 and to exacerbate symptoms among those who do suffer from AMI. Thus, one concern is that the 
extant public health crisis occurring during data collection may influence the generalizability of our estimates. 
To address this concern, we performed a sensitivity analysis of our main models to including a version of the 
PHQ-9 that asked participants to select answers based on their experiences in the 12 months prior, rather than 
the two-week period standard in the PHQ-9 instrument. Our analysis revealed that 10 participants currently 
classified as having AMI would have been classified in the no AMI group if we used our 12-month rather than 
two-week scale, and that doing so did not significantly influence our estimates nor our conclusions, thus giving 
us some added confidence that this study’s findings provide support for the potential moderating effect of AMI 
on elasticity that are not limited to the period of the pandemic during which the data were collected.  
 
Limitations 
 
 We relied upon self-report data on theoretical purchasing, from a convenience-sourced sample of 
participants, thus our ability to provide generalizable estimates is limited. Further study in this area could seek 
to recruit a larger pool of participants with and without AMI to participate in these abuse liability tasks in a lab 
setting, where they are able to interact with alternative products and mimic real-world use more easily. The use 
of Amazon’s Mechanical Turk as a platform for a convenience-sourced participant pool for this study offers 
both benefits and limitations. The limitations to this method are that the sample cannot be generalized to the 
U.S. population of adult smokers, and the participants have self-selected to participate in online work such as 
survey response. While this poses a limitation, as researchers have begun to use MTurk to conduct studies, 
evaluations of its strengths and limitations, as well as best practices, have also emerged. While MTurk does not 
yield a representative sample, it can yield a highly diverse sample, and offer the opportunity to reach 
subpopulations difficult to attract to studies using conventional menthods.126–128,147 We did not control for 
factors that may influence willingness to substitute alternative products, such as prior use and perceptions of 
low nicotine cigarettes or e-cigarettes, nor did we investigate whether menthol or flavored tobacco preference 
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might affect our conclusions, all factors likely correlated with willingness to engage with the alternative 
products and the valuation of such products.148–150 Future studies could include such measures to account for 
this likely source of variation. Finally, while depression is one of the most common mood disorders affecting 
U.S. adults, understanding the extent to which our conclusions generalize across mood and/or behavior 
disorders and their measurement tools would be important in understanding the reach of future policy 
alternatives. 
Conclusion 
 
 Among adult participants with AMI, we observed both higher demand for cigarettes, and that AMI 
moderated the association between price and consumption,  revealing that adults with AMI were more reluctant 
to reduce consumption in the face of rising costs associated with smoking. However, these adults generally 
found alternative products to be acceptable substitutes at rates similar to adults without AMI, though 
willingness to substitute varied significantly by product for all participants. Our results  provide cautionary 
evidence that policymakers should carefully weigh likely responses to increased tobacco prices across 
subgroups of smokers when assessing how successful price policies may be in reducing smoking. In addition, 
the extent to which smokers will substitute alternative, potentially less harmful products varies, demanding 
further inquiry in order to ameliorate rather than exacerbate disparities in use of combustible products under 
future likely regulatory conditions. 
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Table 2-1. Selected Sociodemographic and Tobacco Use Characteristics of the Study Sample (n=407) 
 Total 
Sample 
N=407 
% 
AMI 
Symptoms 
N=201 
% 
No AMI 
Symptoms 
N=206 
%  
P-value1 
Sociodemographic Covariates     
Sex    0.73 
   Male 68.1 67.2 68.8  
   Female 31.9 32.8 31.2  
Age    p<0.01 
   18-24 9.3 11.9 6.8  
   25-34  53.1 61.2 45.2  
   35-44 24.2 18.9 29.1  
   45-54 9.1 6.5 11.7  
   55+ 4.4 1.5 7.3  
 Race/Ethnicity     p<0.01 
   Non-Hispanic Caucasian 49.6 42.8 56.3  
   Non-Hispanic African American 4.4 3.0 5.3  
   Asian 27.4 27.9 27.2  
   Hispanic 15.7 22.4 9.2  
   Other 2.9 4.0 1.9  
Educational Attainment    0.16 
   High School/GED or Less  11.3 12.4 10.2  
   Some college 22.7 18.9 26.7  
   Bachelors or higher 66.0 68.7 63.1  
Annual HH Income    p<0.01 
   Less than $10,000 13.0 17.4 8.7  
   $10,000-$24,999 19.1 25.4 13.1  
   $25,000-$49,999 28.9 28.9 28.2  
   $50,000-$99,999 28.9 22.9 35.0  
   $100,000+ 10.1 5.5 15.1  
Dependence and Tobacco Use     
Nicotine Dependence Score2 2.80 (0.95) 3.04 (0.06) 2.56 (0.67) p<0.01 
Average Weekly Spending on Cigarettes    p<0.01 
   Less than $10 20.9 18.6 23.2  
   $10-$24 29.9 29.3 30.1  
   $25-$49 20.9 16.0 25.6  
   $50-$150 28.3 36.2 21.2  
Smoking Motivation, Peer and Family Effects     
When I feel blue or want to take my mind off 
cares and worries, I smoke cigarettes. 
   0.01 
   Yes 46.9 53.2 40.8  
   No 53.1 46.8 59.2  
Peer/Family Perception of Tobacco Use    p<0.01 
   Positive/Very Positive 20.4 29.1 10.5  
   Negative/Very Negative 79.6 70.9 89.5  
Family History AMI    p<0.01 
   Yes 46.7 64.4 29.1  
   No 53.3 35.6 70.9  
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1P-value represents the test statistic from Pearson’s chi-square tests for significant between-groups 
differences.2Mean and standard error reported.   
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Table 2-2. Demand for Own Brand Cigarettes (n=407) 
 Price Elasticity of 
Demand 
n=407 
β (SE) 
1) AMI, ln(Price), AMI*ln(Price) Only  
   a. Price -0.796 (0.035) 
   b. AMI 0.901 (0.249) 
   c. AMI*Price 0.198 (0.051) 
2) + Demographics  
a. Price -0.792 (0.035) 
b. AMI 0.801 (0.262) 
c. AMI*Price 0.193 (0.051) 
3) + Demographics, dependence, and tobacco 
use 
 
a. Price -0.717 (0.026) 
b. AMI 0.233 (0.246) 
c. AMI*Price 0.163 (0.052) 
4) + Demographics, dependence, tobacco use, 
smoking motivation, peer and family 
effects 
 
a. Price -0.788 (0.041) 
b. AMI -0.278 (0.286) 
c. AMI*Price 0.133 (0.600) 
Bolded values indicate p<0.05 
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Table 2-3. Cross Product Price Elasticities of Demand 
 Low Nicotine 
Cigarette Condition 
n=407 
β (SE) 
Same Nicotine E-
cigarette 
Condition 
n=406 
β (SE) 
Reduced Harm E-
cigarette 
Condition 
n=406 
β (SE) 
Reduced Exposure 
E-cigarette 
Condition 
n=407 
β (SE) 
5) AMI, ln(Price), AMI*ln(Price) Only     
a. Price 0.106 (0.042) 0.119 (0.039) 0.063 (0.031) 0.057 (0.035) 
b. AMI 1.598 (0.335) 2.004 (0.345) 1.600 (0.345) 1.658 (0.355) 
c. AMI*Price 0.001 (0.055) -0.025 (0.050) 0.015 (0.042) 0.001 (0.044) 
6) + Demographics     
a. Price 0.106 (0.042) 0.122 (0.040) 0.063 (0.031) 0.057 (0.035) 
b. AMI 1.098 (0.340) 1.566 (0.359) 1.101 (0.368) 1.295 (0.384) 
c. AMI*Price -0.001 (0.055) -0.029 (0.050) 0.015 (0.042) 0.005 (0.045) 
7) + Demographics, dependence, and 
tobacco use 
    
a. Price 0.107 (0.043) 0.122 (0.040) 0.062 (0.031) 0.057 (0.035) 
b. AMI 0.660 (0.344) 1.276 (0.376) 0.951 (0.385) 1.115 (0.400) 
c. AMI*Price 0.010 (0.057) -0.029 (0.051) 0.015 (0.042) 0.005 (0.045) 
8) + Demographics, dependence, 
tobacco use, smoking motivation, 
peer and family effects 
    
a. Price 0.110 (0.051) 0.147 (0.046) 0.059 (0.035) 0.093 (0.039) 
b. AMI 0.204 (0.409) 1.233 (0.435) 0.830 (0.478) 0.868 (0.477) 
c. AMI*Price 0.020 (0.067) -0.024 (0.061) 0.050 (0.051) -0.012 (0.054) 
Bolded values indicate p<0.05 
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Table 2-4. Additional Abuse Liability Outcomes for Own-Brand Cigarette Purchasing Behavior 
 ln(Intensity)1 
n=392 
β (SE) 
Breakpoint2 ($) 
n=395 
β (SE) 
ln(Omax)1 
n=395 
β (SE) 
ln(Pmax1) 
n=395 
β (SE) 
 
AMI -0.01 (0.121) 1.31 (0.40) 0.63 (0.19) 0.28 (0.15) 
   + Demographics 0.07 (0.136) 0.97 (0.44) 0.51 (0.22) 0.19 (0.17) 
   + Demographics, dependence, tobacco use -0.15 (0.135) 0.03 (0.43) 0.07 (0.19) -0.07 (0.19) 
   + Demographics, dependence, tobacco use, 
smoking motivation, peer and family effects 
-0.16 (0.164) -0.93 (0.52) -0.30 (0.23) -0.46 (0.20) 
Bolded values indicate p<0.05 
1Intensity, Omax and Pmax coefficients represent change in log value of each outcome associated with AMI and other covariates. Mean Omax (original 
units: $) among sample participants was 39.1 (117.6); Mean Pmax (original units: $) among sample participants was $5.12 (3.75); mean Intensity was 
19.01 (26.49). 
2Sample mean breakpoint was $6.21(4.02). 
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Chapter 3 A Longitudinal Assessment of Nicotine Dependence, Mental Health, 
and Attempts to Quit Smoking: Evidence from Waves 1-4 of the Population 
Assessment of Tobacco and Health (PATH) Study. 
  
Abstract 
 
Background: Adult smokers with symptoms of any mental illness (AMI) are highly dependent on nicotine and 
may face additional difficulty quitting smoking. While there is evidence that adult smokers with AMI have high 
dependence, there is insufficient evidence regarding the unique role that AMI may play in moderating the 
relationship between dependence and cessation outcomes over time. 
Methods: 7,290 current established adult smokers at Wave 1 (2013-2014) of the PATH Study also participated 
in data collection in Waves 2-4 (2014-2018). Fixed-effects linear probability models were fit to the data, 
modeling associations between AMI, nicotine dependence, and the 1) likelihood of achieving cessation during 
the study period, 2) making a cessation attempt within the previous 12 months, and 3) past 30-day total 
consumption of cigarettes.  
Results: Adults who experienced both any AMI symptoms and high dependence were 3.8 percentage points 
(PP) less likely to achieve cessation at any point during the study period (p<0.01), and smoked 76.5 more 
cigarettes per month (95% CI: 48.6, 103.4), than those with high dependence alone, despite being as likely to 
attempt to quit. Adults with high internalizing symptoms and high dependence were 3.6 PP less likely to report 
cessation (p<0.05).   
Conclusions:  Adults with AMI are particularly affected by the burden of tobacco use, in part because of the 
likely interaction between nicotine dependence and AMI.  Tobacco control efforts that focus on this interplay 
may provide an opportunity to better target interventions for this vulnerable population. 
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Introduction 
 
 One in four people in the U.S. are estimated to experience “any mental illness” (AMI); however this 
group represents an estimated 40% of annual cigarette consumption,64,65,142 and experience of AMI has been 
linked to increased smoking initiation 13,38 and more difficulty quitting.5,12 The most common causes of death 
among people with AMI are heart disease, cancer, and lung disease, which can all be caused by smoking.19,151  
Previous research has identified possible pathways to explain this disparity, including the suggestion that 
adults with AMI have higher abuse liability, or the likelihood of persistent tobacco use or dependence,5,24 than 
adult smokers without AMI. Abuse liability may be higher among those with AMI due to use of tobacco, in 
part, to help cope with symptoms of mental illness.9,24,25 Previous research on smoking expectancies among 
youth,40 adults,41 and adults with AMI has identified that adults experiencing mental illness are unique in that 
they report the positive expectancy “reduction of negative affect” as most important factor in guiding their 
decisions about smoking.42–44 Negative affect in the case of adults with AMI refers to adverse symptoms they 
may experience due to mental illness. Smoking, therefore, is one tool that adults with mental illness may rely 
upon to cope with symptoms,152 and previous studies on mental health and smoking have linked AMI with 
higher nicotine dependence,5 and with reduced success when attempting to quit smoking.153 
Quitting smoking has been linked to significant improvements in symptoms of mental illness and overall 
well-being.154 Adult smokers with AMI may be interested in quitting but less likely to attempt to quit.155 
However, at least one systematic review found that smokers with AMI may be just as motivated to make a quit 
attempt as those without.156 Additionally, smokers suffering from specific illnesses such as depression may be 
able to reduce or quit smoking without exacerbating symptoms of their illness,103 and can be successful in 
cessation attempts if offered sufficient support.24,25  However, it is rare for behavioral health specialists to 
incorporate medication or behavioral strategies to promote smoking cessation among patients with AMI, 
leading some to call smoking among those with AMI a “neglected epidemic.” 67  
Cessation research among adults with AMI has relied primarily on cross-sectional data,5,13,38 or has been 
conducted among smaller samples of smokers with specific diagnoses,42,43,157 making it difficult to generalize 
findings and inform policymaking. As cessation is the primary means of reducing the risk of smoking-related 
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disease among current smokers,158 a more complete understanding of how dependence and cessation are linked 
among adults with AMI is a critical area of investigation. Previous studies have also not explicitly investigated 
whether the role of nicotine dependence in cessation outcomes varies across smokers with and without 
symptoms of mental illness. While adults with AMI tend to have higher nicotine dependence, it is unclear how 
AMI may moderate the relationship between nicotine dependence and smoking behavior, thus providing an 
additional barrier for highly nicotine dependent adults at risk for tobacco-related disease to quit. This study uses 
longitudinal, nationally-representative data from a cohort of U.S. adult smokers who participated in four waves 
of the Population Assessment for Tobacco and Health (PATH) Study to explore associations between 
experiencing AMI symptoms during the study period, high nicotine dependence, and variation in cessation 
outcomes over time to inform more targeted tobacco prevention and control strategies.  We hypothesize that 
adults reporting symptoms of AMI will be less likely to report having quit smoking compared to adults without 
these symptoms, and that dependence will moderate the association between AMI and cessation outcomes. 
Conceptual Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 Figure 3 illustrates a hypothetical relationship between symptoms of mental illness and increased 
dependence on cigarettes and therefore stronger preference to continue smoking, and more dependent or 
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addicted smokers are then likely to have more difficulty reducing or ceasing tobacco use. Reducing tobacco use 
can induce symptoms of physical and behavioral withdrawal, which may make it more difficult for smokers 
who are highly dependent and using smoking to cope with negative affect to make a quit attempt, and to 
maintain cessation. Smokers with AMI may use cigarettes because use breeds dependence, and because they 
believe smoking helps them cope with symptoms. As previous research has shown that adults with AMI may 
have high nicotine dependence (physically and behaviorally), adults with AMI may be more reliant and less 
able to reduce consumption of cigarettes to zero (cessation). 
Hypotheses 
 
 H3 (a) Adults with AMI will report higher nicotine dependence, (b) have a lower probability of making 
a cessation attempt or achieving self-reported cessation during the study period.  Further, (c) dependence will 
moderate the association between AMI and cessation outcomes. 
Methods 
 
Sample 
Data was obtained for 7,290 adults who were current, established cigarette smokers during data 
collection for Wave 1 (October 2013 - December 2014) of the PATH Study, and who participated in the 
subsequent three waves of data collection (Wave 2: October 2014 - October 2015; Wave 3: October 2015- 
October 2016; Wave 4: October 2017- October 2018). Current, established cigarette smoking is defined in the 
PATH Study as having smoked at least 100 cigarettes in a participant’s lifetime and currently smoking every 
day or some days.159 The PATH study is a nationally representative, longitudinal cohort study of U.S. youth and 
adult smokers and non-smokers. Participants were selected based on a multi-stage area, probability design, and 
asked about current and former tobacco use, attitudes toward and perceptions of tobacco products, exposure to 
marketing and advertising, and demographic and health information. Adult tobacco users, African Americans, 
and young adults were oversampled, and survey weights allow estimates to be generalized to the non-
institutionalized U.S. population.160 The PATH Study offers all-waves weights for participants surveyed in 
Waves 1-3 who remained eligible to participate in Wave 4.161 All waves-weights were used to provide 
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generalizable estimates and allow for appropriate non-response adjustments. The weighted Wave 1 to Wave 4 
response rate among adult survey participants was 74%.161 
Smoking Behavior Measures 
 
Cessation: Participants were asked in each wave to describe their current smoking behavior, and 
participants who were current, established smokers at Wave 1 and reported currently smoking “Not at all” and 
had not smoked within the past 30 days were classified as having quit smoking (Cessation: Yes/No).  
Quit Attempts: All participants currently smoking in each wave were asked whether they had tried to 
quit smoking completely within the past 12 months (Attempt: Yes/No). 
Cigarette Consumption: All participants who reported smoking “Some days” were asked how many 
days they smoked in the previous 30 days. “Every day” smokers were assigned a score of 30. Some-day 
smokers were also asked how many cigarettes on average they smoked on days smoked, every-day users were 
asked on average how many cigarettes they now smoked every day. Per wave, participants still smoking were 
assigned a total, monthly cigarette consumption as a measure of intensity of consumption by multiplying the 
number of days smoked by the number of cigarettes per day (CPD). This value was transformed for analysis 
using the natural log.162 
Health Care and Cessation Measures 
 
All participants were asked in each wave whether they had seen a medical doctor in the previous 12 
months (Yes/No), if any health care professional had advised quitting smoking (Yes/No), and, among those who 
attempted quitting, if they had used any cessation support during their last attempt, to quit completely, and to 
avoid negative effects of quitting smoking. Cessation support options included:  1) nicotine replacement therapy 
(NRT); 2) prescription cessation aids; and 3) Other cessation support (Assigned indicator if used support from 
family or friends, counseling or self-help materials, or tried using other tobacco products to help quit smoking). 
Mental Illness Measures 
Symptoms of AMI were assessed in PATH using instruments from the Global Appraisal of Independent 
Needs Assessment-Short Screener (GAIN-SS), a validated, clinically-relevant tool for assessing likelihood of 
mental illness, as well as how recently those symptoms were experienced.163 The GAIN-SS Instrument is part of 
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the NIH-sponsored PhenX Toolkit of recommended research protocols, for use among youth and adults in a 
wide variety of settings.164 This instrument was further adapted for the PATH Study,13 and participants were 
assessed using three subscales: Substance Abuse Symptoms, Internalizing Problem Symptoms, and 
Externalizing Problem Symptoms. As our study population is comprised of established smokers, we did not to 
include the substance abuse scale (which includes items related to smoking behavior) in our analyses, and 
primary results were not sensitive to excluding the substance abuse subscale. High internalizing problem scores 
are most closely associated with disorders such as depression, anxiety, trauma, and (at extremely high levels) 
schizophrenia and bipolar disorder, while high externalizing problem scores are most closely associated with 
diagnoses of attention deficit disorders and impulsivity.163  
Participants were asked how frequently (never, over a year ago, 2-12 months ago, or within the past 
month) they experienced 4 symptoms from the internalizing scale and 7 symptoms from the externalizing scale. 
Possible scores were 0-4 for internalizing problems and 0-7 for externalizing problems. Consistent with 
previously validated and clinically-relevant cut points, participants were assigned a score per subscale of 0-1 
(unlikely to have a diagnosis or need services), 2-3 (moderate, indicating possible diagnosis), or 4 for 
internalizing problems and greater than or equal to 4 for externalizing problems (indicating high severity and 
likely need for services).13,163,165 While some previous, cross-sectional studies have focused on lifetime 
AMI,13,38 we focused on high AMI symptoms in the time period most closely linked to our measured smoking 
behavior. Participants who received a high severity score for symptoms in the past year during any wave were 
classified as having AMI during the study period. Participants were also assigned a “high internalizing” or 
“high externalizing” indicator representing whether they had received a high severity score on each subscale at 
any point during the survey period.  
Nicotine Dependence Measures 
Nicotine dependence was assessed using a 16-item composite scale of questions from the Wisconsin 
Inventory of Smoking Dependence Motives (WISDM), the Nicotine Dependence Syndrome Scale (NDSS), and 
the American Psychological Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM) 
measure for Impaired Control. This combined scale was developed using the PATH Study data, to provide a 
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validated common instrument for assessing nicotine dependence across users of different tobacco products.166 
While the PATH Study includes several dependence measures, WISDM includes dependence motives such as 
negative reinforcement, cognitive enhancement, and social reinforcement that may be particularly relevant to 
tobacco use among adults experiencing AMI. All 16 questions asked participants to rate statements about 
dependence on tobacco products on a 5-item Likert scale (from “Not true of me at all” to “Extremely true of 
me”). Participants received an average score during each wave, with higher scores indicating higher 
dependence.166,167 In order to assess the unique association between smoking behaviors and the experience of 
both high AMI symptom severity and high nicotine dependence, an indicator in each wave for high dependence 
was created to denote smokers with a dependence score above the sample median. 
Covariates 
 
 Additional factors associated with variation in smoking behavior and nicotine dependence were 
measured in each wave. We included factors such as past 30-day use of other tobacco products (electronic 
cigarettes, cigars, cigarillos, pipe tobacco, hookah, smokeless products, snus, and dissolvable tobacco), past 30-
day use of alcohol, 168 and having seen a medical professional in the previous 12 months. 
We also included demographic and social factors that varied over time through indicator variables for 
levels of age, educational attainment, and annual household income. 
Statistical Analysis 
 
We described our participant sample using weighted proportions and used weighted Pearson’s chi- squared 
tests and t-tests to detect any systematic differences among participants based on whether they experienced high 
AMI symptoms at any point during the study period. We employed a fixed-effects linear probability model to 
provide adjusted estimates for associations between our smoking outcomes and the interaction of a high AMI 
symptom score with high dependence, controlling for high dependence, other tobacco and alcohol use, and 
sociodemographic covariates. Fixed-effects models in panel data control for within-individual unobserved, time 
invariant confounders.95We employed the same method to test for associations between smoking behavior and 
specific interactions between a high internalizing symptom score and high dependence, and high externalizing 
score and high dependence. Finally, we used a similar approach to provide adjusted estimates for the association 
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between health behaviors and cessation support and interactions between high internalizing or externalizing 
symptom scores and high dependence. Estimates for cigarette consumption were retransformed for 
interpretability, using a smearing factor to account for nonparametric, heteroskedastic distribution of regression 
residuals,169 and standard errors bootstrapped to provide a confidence interval for the retransformed 
estimates.170 Because participants who experienced AMI symptoms at any point during the study period were 
classified as having AMI, AMI alone was time-invariant in our models, and therefore only the interaction 
between AMI and high dependence may be estimated in our models. The probability of making a type I error of 
0.05 was used as the threshold for all tests, and all analyses were performed using Stata 15.1 (College Station, 
TX).  
Results 
 
Participant Characteristics and Unadjusted Associations between AMI Status and Participant Characteristics 
in Wave 1 
 Population weighted estimates (Table 3-1) indicated that participants who were cigarette smokers in 
Wave 1 were primarily composed of Non-Hispanic Caucasians (69.9%), between the ages of 25 and 54 
(64.1%), who earned a high school education or less (54.2%), with an annual household income between 
$10,000 and $49,999 (53.0%). 28.8% of the sample at Wave 1 was classified as having AMI (receiving a high 
score for either internalizing or externalizing problems), and 52.8% of participants were classified as having 
high Wave 1 nicotine dependence. The mean number of days smoked in the past 30 days was 26.5, with a mean 
number of cigarettes per day of 10.5. Nearly half (41.4 %) of participants had used other tobacco products in 
addition to cigarettes in the past 30 days, and 59.4% had used alcohol within that time frame. There were 
statistically significant unadjusted differences in nearly all measures by AMI status among Wave 1 smokers, 
with those who had AMI symptoms expressing higher dependence (59.9% vs. 42.0% for those without AMI, 
p<0.01), higher rates of past 30 days use of other tobacco products (48.9% vs. 37.4%, p<0.01), and higher rates 
of past 30 day alcohol use (63.9% vs. 57.6%, p<0.01). There were also statistically significant differences by 
AMI status by sex, race/ethnicity, age, educational attainment, and annual household income: participants with 
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AMI were more likely to be female, younger, non-Hispanic Caucasian, to have achieved a high school 
degree/GED or less, and to have a lower annual income (p<0.05).  
Adjusted Associations between AMI Symptoms, Nicotine Dependence, and Smoking Behavior 
 Participants who reported both high levels of AMI symptoms from either scale during the survey period 
and high nicotine dependence were 3.8 percentage points (PP) less likely to have achieved self-reported 
cessation (p<0.01) and reported smoking more cigarettes per month (𝛽=0.171, p<0.05) than those with AMI 
symptoms alone (Table 3-2).  This estimate from the natural log model translates to 76.5 more cigarettes per 
month (95% CI: 48.6, 103.4). High dependence without high AMI symptoms was associated with increased 
monthly cigarette consumption (𝛽=0.202, p<0.01) or 126.2 cigarettes (95% CI: 98.9, 150.2), but also with a 2.7 
PP increase in the likelihood of achieving cessation. Past 30-day use of other tobacco products was associated 
with reduced likelihood of achieving cessation (-1.3 PP, p<0.01), but increased probability of reporting a quit 
attempt (2.1 PP, p<0.05). 
Participants who reported both high levels of internalizing symptoms during the survey period and high 
nicotine dependence were 3.6 percentage points (PP) less likely to achieve cessation during the survey period 
(p<0.05) (Table 3-3). 
Past 30-day use of alcohol was associated with a 3.6 PP reduction in the likelihood of cessation 
(p<0.01), whereas increased educational attainment predicted a higher probability of making a quit attempt: 
adults with a Bachelor’s degree or higher were 8.6 PP more likely to report cessation than those with a high 
school degree or less (p<0.01). Reporting a past 12-month doctor visit was associated with an increased 
likelihood of cessation (1.7 PP, p<0.01) and making a quit attempt (2.0 PP, p<0.05). Time was also significantly 
associated with increased likelihood of achieving cessation (Wave 2: 11.0 PP; Wave 3: 15.1 PP, p<0.01; Wave 
4: 16.8 PP, p<0.01), making a quit attempt (Wave 3: 13.7 PP, p<0.01); Wave 4: 12.5 PP, p<0.01), and for 
decreases in overall cigarette consumption (-27.6 cigarettes (CI: -42.2, -15.2) in Wave 2 (𝛽=-0.214, p<0.01),  -
54.7 cigarettes (CI: -66.4, -39.9) in Wave 3 (𝛽=-0.400, p<0.01), and -55.1 cigarettes (CI: -68.5, -39.2) in Wave 
4 (𝛽=-0.406, p<0.01).  
Adjusted Associations between AMI Symptoms and Health Behaviors 
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 Having either high internalizing or externalizing symptoms and high dependence was associated with an 
increase in the probability of reporting seeing a medical doctor within the previous 12 months (2.3 PP and 2.7 
PP respectively, p<0.05); Table 3-4), and with increased likelihood of using NRT during a recent quit attempt 
(5.1 PP, p<0.05). High dependence was associated with a 3.6 PP increase in the probability of reporting that a 
healthcare professional had advised quitting (p<0.05). AMI plus high dependence as well as high dependence 
alone were not significantly associated with reporting the use of any cessation aid or use of a prescription 
cessation aid. Past 30-day users of other tobacco products were 3.6 PP (p<0.01) less likely to report that a 
healthcare professional advised quitting, and more likely to report use of a cessation aid (8.5 PP, p<0.01). 
Finally, the likelihood of reporting seeing a medical doctor, using a non-NRT or non-Rx cessation aid, and 
using NRT significantly differed over time, with respondents less likely to report all three behaviors in Waves 2 
through 4 than Wave 1 (p<0.01).  
Discussion 
 
While significant progress has been achieved in reducing overall smoking rates among U.S. adults,171 
adult smokers with symptoms of AMI suffer from significantly higher smoking rates than the general 
population65 and increased rates of tobacco-related morbidity and early mortality.18 Previous studies have found 
higher rates of nicotine dependence among smokers with AMI symptoms and diagnoses,5 and that cessation 
success may be lower across all diagnoses.25,38 Longitudinal, diagnosis-specific cohort studies with smaller 
samples of adult participants have also indicated that adults with AMI may be equally motivated to quit,156,172 
and that they may be able to do so with appropriate support, although behavioral health specialists may still be 
reluctant to incorporate smoking cessation into therapeutic strategies.66 This study offers specific insight into an 
additional aspect of the association between AMI and nicotine dependence, namely whether smokers 
experiencing both high levels of AMI symptoms and high nicotine dependence might be at a particular 
disadvantage when attempting to reduce or quit smoking.  
To understand if AMI moderates the association between dependence and smoking cessation over time, 
this study tested whether having both high levels of AMI symptoms during the study period and high nicotine 
dependence was associated with variation in the likelihood of making a quit attempt, of achieving self-reported 
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cessation at any point during the study period, and of variation in cigarette consumption. We found that adults 
with any AMI symptoms and high dependence, and specifically both high internalizing symptoms and high 
dependence, reported less success achieving short-term, self-reported cessation than those with high dependence 
alone. Despite this finding, participants suffering from high AMI symptoms and high dependence did not 
exhibit significant variation in the likelihood of making a quit attempt, consistent with some previous studies 
assessing motivation to quit,156 and suggesting that these smokers may simply be less successful at achieving 
cessation than those coping with high dependence alone. We also tested the sensitivity of our main findings 
regarding smoking behavior to use of alternative strategies for modeling whether symptoms of AMI may be 
considered time-invariant in this relationship, the approach taken in this study and those that employ a lifetime 
measure of AMI.13 To do so, we tested whether our main conclusions would differ under assumptions that allow 
AMI status to vary based on score per wave of the GAIN-SS instrument (see Appendix 3-A). We found that 
varying our approach for classifying AMI as either a fixed or varying symptom condition did have an impact on 
the conclusions we would draw from these models. This suggests there may be further study to do in this area, 
as we don’t yet know how closely variation in GAIN-SS score actually reflects change in symptoms or need for 
coping mechanisms at different survey points. Or, if the underlying condition will affect symptoms and 
behavior despite minor variation in classification based on scale responses. 
 Despite lower rates of success, those with either high internalizing or externalizing symptoms and high 
dependence were more likely to report contact with the health system within the previous 12 months. And, 
while counterintuitive, the increased probability of achieving cessation at some point during the survey period 
among those with high dependence may be due, in part, to increased likelihood of reporting being advised to 
quit by a healthcare professional. This may help explain why we observed a comparable likelihood of making a 
quit attempt among two distinct groups of adult smokers generally perceived to be highly vulnerable to reduced 
cessation success. Reduced success in cessation among those with AMI, despite likelihood of attempting to quit, 
lends support for previous work 66 which suggests that cessation support may need to be tailored to account for 
diagnosis-specific AMI symptoms to help highly dependent smokers combat lower probability of cessation 
success.  
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Limitations 
 
 Several limitations should be considered when evaluating the internal and external validity of this study. 
All data were self-reported, thus there may be measurement error in tobacco use behaviors and dependence 
scores. The PATH study does not include the full range of questions from the WISDM, and questions referred 
to all tobacco products that are not e-cigarettes (e-cigarette dependence was queried separately) if a participant 
uses more than one of these products. We were unable to validate the assumption that smokers with AMI may 
smoke to cope with symptoms they experience, nor do we have information available about whether 
participants with AMI had been treated by a mental health professional, which could influence both symptoms 
and smoking behavior. Despite these limitations, a particular strength of this study is that it relied upon self-
reported symptoms of mental illness without diagnostic information. Only 43.3% of adults with symptoms of 
AMI received treatment in 2018, and the average time between symptom onset and treatment is 11 years.173 By 
capturing likely AMI in a national sample of smokers rather than relying on diagnosis or treatment information, 
our results may offer generalizable insight for many U.S. adults. Regarding the statistical approach, fixed 
effects models are designed to control for unobserved confounders within individuals that do not change over 
time but may produce biased estimates if important time-varying confounders are not accounted for. Finally, the 
study followed smokers over approximately 3 time periods (Wave 1 to Wave 4).   Given the number of attempts 
most smokers make before achieving cessation, and the high rate of relapse, future work should endeavor to 
follow smokers beyond several years. 
Conclusion 
 
 One in five U.S. adults is estimated to experience symptoms of AMI, and this group remains vulnerable 
to initiating and continuing smoking, and tobacco-related early mortality, despite decades of progress among the 
general population. This study provides further evidence that certain groups of AMI symptoms and disorders 
may put nicotine-dependent adults at particular disadvantage when attempting to quit or reduce smoking, 
despite their attempts. Policymakers could be best served to focus not merely on motivating quit attempts 
among adults with AMI, as they already appear likely to attempt cessation.  Research related to how best to 
tailor sustained cessation support to adults with certain classes of AMI symptoms may prove more effective in 
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turning attempt into success, particularly in light of the fact that these smokers are more likely to report contact 
with the healthcare system. Further work could leverage the power of additional waves of PATH data to better 
understand the trajectory of smoking behavior among adults with AMI who are attempting to reduce or cease 
smoking, to inform policy targeted to alleviating this disparity. 
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Table 3-1. Weighted Descriptive Characteristics of Wave 1 Current, Established Adult Cigarette Smokers in the Population Assessment of 
Tobacco and Health (PATH) Study 
 Total Sample 
n=7,290 
N1=41,001,960 
% (CI) 
AMI Symptoms 
n=2,249 
N=11,823,963 
% (CI) 
No AMI Symptoms 
n=5,041 
N=29,177,997 
% (CI) 
p-value2 
High Nicotine Dependence3    p<0.01 
   Yes 47.2 (45.6, 48.7) 59.9 (57.5, 62.3) 42.0 (40.4, 43.6)  
   No 52.8 (51.3, 54.3) 40.1 (37.6, 42.6) 58.1 (56.4, 59.6)  
Number of Days Smoked4 26.49 (0.13) 26.47 (0.20) 26.50 (0.16) 0.99 
Number of Cigarettes4 
Smoked 
10.53 (0.14) 10.73 (0.21) 10.45 (0.17) 0.24 
Past 30-Day Other Tobacco 
Use 
   p<0.01 
   Yes 41.4 (40.0, 42.7) 48.9 (46.4, 51.3) 37.4 (35.9, 39.0)  
   No 58.6 (57.3, 60.0) 51.1 (48.7, 53.6) 62.6 (61.0, 64.1)  
Past 30-Day Alcohol    p<0.01 
   Yes 59.4 (57.9, 61.0) 63.9 (61.3, 66.3) 57.6 (55.9, 59.4)  
   No 40.6 (39.1, 42.1) 36.1 (33.7, 38.7) 42.4 (40.6, 44.1)  
Made a Doctor Visit in the 
Previous 12 Months 
   p<0.01 
   Yes 72.6 (71.4, 73.9) 76.2 (74.2, 78.0) 71.2 (69.7, 72.7)  
   No 27.4 (26.1, 28.6) 23.8 (22.0, 25.8) 28.8 (27.3, 30.3)  
Male 54.7 (53.5, 56.0) 48.7 (46.5, 51.0) 57.2 (55.7, 58.6) p<0.01 
Age    p<0.01 
   18-24 14.2 (13.4, 15.1) 21.4 (19.5, 23.4) 11.4 (10.5, 12.3)  
   25-34 24.7 (23.7, 25.8) 28.6 (26.7, 30.6) 23.2 (21.9, 24.5)  
   35-44 19.2 (18.0, 20.4) 18.8 (17.0, 20.9) 19.3 (18.1, 20.6)  
   45-54 20.2 (19.2, 21.3) 17.9 (16.2, 19.9) 21.1 (19.9, 22.4)  
   55-64 15.0 (13.9 (16.1) 11.0 (9.60, 12.6) 16.6 (15.3, 18.0)  
   65+ 6.7 (6.0, 7.5) 2.3 (1.6, 3.2) 8.5 (7.5, 9.5)  
Race/ethnicity    p<0.01 
   Caucasian 69.9 (68.7, 71.1) 71.7 (69.5, 73.8) 69.2 (67.7, 70.7)  
   African American 13.3 (12.5, 14.1) 10.6 (9.4, 12.0) 14.4 (13.4, 15.4)  
   Hispanic 11.1 (10.4, 11.7) 11.0 (9.6, 12.6) 11.1 (10.3, 11.9)  
   Other 5.8 (5.2, 6.43) 6.7 (5.6, 7.8) 5.4 (4.7, 6.1)  
Education    p<0.01 
   High School/GED or less 54.2 (52.9, 55.6) 51.1 (48.8, 53.8) 55.4 (53.9, 56.9)  
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 Total Sample 
n=7,290 
N1=41,001,960 
% (CI) 
AMI Symptoms 
n=2,249 
N=11,823,963 
% (CI) 
No AMI Symptoms 
n=5,041 
N=29,177,997 
% (CI) 
p-value2 
   Some College 34.4 (33.0, 35.7) 38.7 (36.5, 40.9) 32.6 (31.1, 34.1)  
   Bachelor’s or higher 11.4 (10.7, 12.2) 10.0 (8.8, 11.4) 12.0 (11.1, 13.0)  
Annual HH Income    p<0.01 
   Less than $10,000 21.2 (19.8, 22.6) 28.4 (26.2, 30.7) 18.2 (16.7, 19.8)  
   $10,000-$24,999 28.0 (26.6, 29.6) 29.9 (27.7, 32.2) 27.3 (25.5, 29.1)  
   $25,000-$49,999 25.0 (23.9, 26.2) 21.6 (19.6, 23.7) 26.5 (25.0, 28.0)  
   $50,000- $99,999 18.6 (17.4, 19.9) 14.2 (12.3, 16.4) 20.5 (19.0, 22.0)  
   $100,000+ 7.1 (6.4, 8.0) 5.9 (4.8, 7.3) 7.6 (6.7, 8.7)  
1N represents the population of U.S. adults to which the sample generalizes, adult All-Wave weights were used for estimates. 
2Pearson’s chi squared tests and t-tests used to determine p-values. Bolded p-values indicate statistical significance <0.05. 
3Represents Wave 1 nicotine dependence score higher than the median value of 2.83. 
4All smoking behavior measures refer to past 30-day use; cigarettes smoked refers to average consumption on days smoking in the past 30 days; 
weighted sample means and standard errors reported. 
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Table 3-2. Associations Between Any AMI Symptoms, Dependence, and Smoking Behavior  
(Waves 1-4) Among Wave 1 Current, Established Smokers (n=7290) 
 Log Cigarette 
Consumption 
(Past 30 Days)1 
𝛽 (SE) 
n=7,020 
Achieving “Non-
Smoking” Status 
𝛽 (SE) 
n=7,111 
Making a Quit 
Attempt 
𝛽 (SE) 
n=7,072 
Any AMI Symptoms + High 
Dependence2 
0.171 (0.071) -0.038* (0.013) -0.007 (0.022) 
High Dependence 0.202* (0.052) 0.027* (0.009) -0.018 (0.016) 
Past 30-Day Other Tobacco 
Use 
-0.041 (0.030) -0.013 (0.006) 0.021 (0.009) 
Past 30-Day Alcohol Use 0.022 (0.036) -0.036* (0.007) -0.011 (0.011) 
Past 12-Month Doctor Visit -0.032 (0.039) 0.017* (0.006) 0.021 (0.010) 
Age    
   18-24 Ref Ref Ref 
   25-34 0.006 (0.072) 0.025 (0.012) 0.009 (0.021) 
   35-44 -0.001 (0.110) 0.031 (0.020) 0.014 (0.035) 
   45-54 0.043 (0.146) 0.034 (0.027) -0.017 (0.046) 
   55-64 0.084 (0.184) 0.032 (0.033) 0.032 (0.056) 
   65+ 0.269 (0.253) 0.027 (0.044) 0.072 (0.075) 
Education    
   HS/GED or Less Ref Ref Ref 
   Some College -0.037 (0.061) 0.006 (0.011) -0.003 (0.018) 
   Bachelor’s or higher -0.072 (0.130) 0.033 (0.024) 0.086 (0.037) 
Annual HH Income    
   Less than $10,000 Ref Ref Ref 
   $10,000-$24,999 0.093 (0.048) 0.010 (0.007) 0.002 (0.013) 
   $25,000-$49,999 0.126 (0.053) 0.014 (0.009) -0.006 (0.016) 
   $50,000- $99,999 0.219 (0.062) 0.012 (0.012) -0.001 (0.019) 
   $100,000+ 0.161 (0.086) 0.030 (0.018) -0.005 (0.027) 
Time    
   Wave 1 Ref Ref Ref 
   Wave 2 -0.215* (0.028) 0.110* (0.005) -0.010 (0.008) 
   Wave 3 -0.401* (0.031) 0.152* (0.005) 0.136* (0.010) 
   Wave 4 -0.406* (0.034) 0.168* (0.006) 0.125* (0.010) 
Bolded p-values indicate statistical significance <0.05, * indicates p<0.01. 
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1Total consumption represents the number of days smoked (past 30 days) multiplied by the average number of cigarettes smoked per day during that 
period.  
2Represents participants who experienced any symptoms of AMI during the study period and exhibited an average dependence score>median 
dependence score per wave. 
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Table 3-3. Associations Between Internalizing and Externalizing Behaviors, Dependence, and  
Smoking Behavior (Waves 1-4) Among Wave 1 Current, Established Smokers (n=7290) 
 Log Cigarette 
Consumption 
(Past 30 Days)1 
𝛽 (SE) 
n=7,020 
Achieving “Non-
Smoking” Status 
𝛽 (SE) 
n=7,111 
Making a Quit 
Attempt 
𝛽 (SE) 
n=7,072 
High Internalizing Symptoms 
+ High Dependence2 
0.135 (0.084) -0.036 (0.016) 0.007 (0.025) 
High Externalizing Symptoms 
+ High Dependence2 
0.051 (0.085) -0.018 (0.016) -0.030 (0.026) 
High Dependence 0.213* (0.040) 0.029* (0.009) -0.015 (0.015) 
Past 30-Day Other Tobacco 
Use 
-0.041 (0.030) -0.013 (0.006) 0.022 (0.010) 
Past 30-Day Alcohol Use 0.022 (0.038) -0.036* (0.007) -0.011 (0.011) 
Past 12-Month Doctor Visit -0.032 (0.033) 0.017* (0.006) 0.020 (0.010) 
Age    
   18-24 Ref Ref Ref 
   25-34 0.007 (0.072) 0.025 (0.014) 0.009 (0.021) 
   35-44 -0.001 (0.110) 0.031 (0.022) 0.015 (0.035) 
   45-54 0.045 (0.146) 0.034 (0.029) -0.017 (0.046) 
   55-64 0.085 (0.184) 0.032 (0.036) 0.032 (0.056) 
   65+ 0.271 (0.253) 0.027 (0.044) 0.071 (0.075) 
Education    
   HS/GED or Les Ref Ref Ref 
   Some College 0.037 (0.061) 0.006 (0.011) -0.003 (0.018) 
   Bachelor’s or higher -0.073 (0.130) 0.034 (0.025) 0.086 (0.037) 
Annual HH Income    
   Less than $10,000 Ref Ref Ref 
   $10,000-$24,999 0.093 (0.048) 0.010 (0.007) 0.002 (0.014) 
   $25,000-$49,999 0.126 (0.053) 0.014 (0.009) -0.006 (0.016) 
   $50,000- $99,999 0.218 (0.062) 0.012 (0.012) -0.001 (0.019) 
   $100,000+ 0.160 (0.086) 0.030 (0.018) -0.005 (0.027) 
Time    
   Wave 1 Ref Ref Ref 
   Wave 2 -0.214* (0.028) 0.110* (0.005) -0.010 (0.008) 
   Wave 3 -0.400* (0.031) 0.151* (0.005) 0.137* (0.010) 
   Wave 4 -0.406* (0.034) 0.168* (0.006) 0.125* (0.010) 
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Bolded p-values indicate statistical significance <0.05, * indicates p<0.01. 
1Total consumption represents the number of days smoked (past 30 days) multiplied by the average number of cigarettes smoked per day during that 
period.  
2Represents participants who experienced any symptoms of AMI during the study period and exhibited an average dependence score>median 
dependence score per wave. 
  
 85 
Table 3-4. Associations Between AMI Symptoms and Health Behaviors Among Wave 1 Current, Established Smokers 
 (n=7290) 
 Saw a Medical 
Doctor- Past 
12-Months 
𝛽 (SE) 
n=7,112 
Doctor 
Advised 
Quitting 
Smoking 
𝛽 (SE) 
n=5,209 
Used Any 
Cessation Aid1 
n=4,220 
Used NRT1 
n=3,769 
Used Rx 
Cessation Aid1 
n=3,241 
High Internalizing 
Symptoms 
0.023 (0.010) 0.020 (0.016) 0.007 (0.019) 0.051 (0.021) -0.027 (0.017) 
High Externalizing 
Symptoms 
0.027 (0.011) 0.022 (0.017) 0.026 (0.022) -0.002 (0.022) -0.004 (0.014) 
High Dependence 0.001 (0.009) 0.036 (0.014) 0.005 (0.018) 0.028 (0.021) -0.010 (0.016) 
Past 30-Day Other 
Tobacco Use 
0.003 (0.008) -0.036* (0.013) 0.085* (0.017) -0.035 (0.019) -0.008 (0.014) 
Past 30-Day Alcohol 
Use 
-0.012 (0.009) -0.010 (0.016) 0.022 (0.019) 0.039 (0.022) 0.022 (0.0156) 
Age      
   18-24 Ref Ref Ref Ref Ref 
   25-34 -0.032 (0.020) -0.046 (0.033) 0.046 (0.038) 0.093 (0.042) 0.010 (0.021) 
   35-44 0.002 (0.031) -0.027 (0.052) 0.122 (0.065) 0.099 (0.070) 0.033 (0.045) 
   45-54 0.002 (0.042) 0.040 (0.076) 0.153 (0.089) 0.045 (0.101) 0.103 (0.074) 
   55-64 0.112 (0.050) 0.053 (0.090) 0.045 (0.105) 0.031 (0.122) -0.013 (0.095) 
   65+ 0.180 (0.060) 0.072 (0.114) 0.078 (0.127) -0.019 (0.143) 0.026 (0.113) 
Education      
   HS/GED or Les Ref Ref Ref Ref Ref 
   Some College 0.022 (0.016) -0.018 (0.027) -0.052 (0.030) -0.056 (0.030) -0.008 (0.019) 
   Bachelor’s or 
higher 
0.110* (0.035) 0.050 (0.049) -0.075 (0.062) 0.050 (0.068) -0.001 (0.046) 
Annual HH Income      
   Less than $10,000 Ref Ref Ref Ref Ref 
   $10,000-$24,999 -0.018 (0.012) 0.008 (0.022) 0.023 (0.029)  -0.012 (0.028) -0.011 (0.019) 
   $25,000-$49,999 -0.016 (0.015) -0.004 (0.026) 0.028 (0.033) -0.014 (0.032) -0.014 (0.021) 
   $50,000- $99,999 -0.010 (0.018) 0.003 (0.030) 0.046 (0.038) -0.016 (0.039) 0.010 (0.027) 
   $100,000+ 0.003 (0.024) -0.006 (0.038) 0.018 (0.050) -0.011 (0.053) -0.040 (0.043) 
Time      
   Wave 1 Ref Ref Ref Ref Ref 
   Wave 2 -0.052* (0.008) -0.027 (0.025) -0.067* (0.015) -0.068* (0.017) 0.018 (0.014) 
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 Saw a Medical 
Doctor- Past 
12-Months 
𝛽 (SE) 
n=7,112 
Doctor 
Advised 
Quitting 
Smoking 
𝛽 (SE) 
n=5,209 
Used Any 
Cessation Aid1 
n=4,220 
Used NRT1 
n=3,769 
Used Rx 
Cessation Aid1 
n=3,241 
   Wave 3 -0.038* (0.008) -0.028 (0.025) -0.145* (0.018) -0.143* (0.020) -0.011 (0.015) 
   Wave 4 -0.057* (0.009) -0.044 (0.026) -0.138* (0.019) -0.156* (0.021) -0.007 (0.017) 
Bolded p-values indicate statistical significance <0.05, * indicates p<0.01. 
1Participants who attempted quitting smoking during each wave were asked to mark all methods they used to help quit smoking during their most 
recent quit attempt. 
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Conclusion and Implications 
 
 Despite the success of tobacco prevention policies at reducing smoking prevalence overall among youth 
and adults, adults with mental illness are at high risk for initiating and continuing cigarette use, and we suffer 
from a dearth of evidence among this population. This study leveraged the power of longitudinal, nationally 
representative surveys of cohorts of U.S. adults to investigate whether adults with AMI have responded 
differently to increases in excise tax rates over time, and whether a unique association between AMI and 
nicotine dependence may moderate smoking behavior outcomes for highly dependent adult smokers. Our results 
relying upon historical variation in excise tax rate suggest that, while adults with AMI may be more likely to 
smoke and to have increased cigarette consumption, they do not appear to respond differently to price policies 
than adults without AMI. Our investigation of the role of nicotine dependence in predicting successful quit 
attempts indicates that certain groups of AMI symptoms and disorders may put nicotine-dependent adults at 
particular disadvantage when attempting to quit or reduce smoking, despite their attempts. Our study relying 
upon data from contemporary adult participants revealed that exposing participants to theoretical purchase tasks 
with wider variation in prices than that which we typically observe using excise tax rate predicted that not only 
would those with AMI still generally self-report higher demand, but that they would also be more reluctant to 
reduce demand in the face of rising prices. In addition, they were just as likely as those without AMI to 
substitute one of several lower harm alternative products under certain conditions as the price of their preferred, 
combustible product increased. 
 Taken together, our findings imply that adults with AMI have the potential to have more difficulty 
reducing combustible tobacco use under certain conditions than adults without these symptoms, making it 
imperative that this population remain a high priority for investigators seeking to reduce a significant disparity 
in use rates and combustible tobacco-related health consequences. Our results  provide cautionary evidence that 
policymakers should carefully weigh likely responses to increased tobacco prices across subgroups of smokers 
when assessing how successful price policies may be in reducing smoking. Research related to how best to 
tailor sustained cessation support to adults with certain classes of AMI symptoms may also prove effective in 
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turning attempt into success, particularly in light of the fact that these smokers are equally likely to attempt to 
quit smoking, and to report contact with the healthcare system. Additional areas of focus for future work that 
could significantly advance our knowledge in this area would include investigating the role specific categories 
of AMI symptoms play in predicting these outcomes, assessing how severity of symptoms may impact use 
behaviors in the face of likely policy alternatives, further exploring the role of treatment for mental health in 
influencing tobacco use behaviors, categorizing the degree to which adults with AMI perceive and respond to 
tobacco-related harm or risk reduction communication, and expanding these methods to focus on other 
populations at high risk for initiating and continuing smoking. Without such evidence, there poses a significant 
risk that some groups of smokers may be omitted from critical policy solutions intended to reduce the 
substantial public health burden of combustible tobacco use in the U.S. 
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Appendices 
 
Appendix 1-A 
 
Sensitivity Analysis for AMI Classification Strategies 
 
1. Smoking Participation  
 Threshold: 60 
(<60 indicates AMI) 
Threshold: 68 
(<68 indicates AMI) 
Threshold: 76 
(<76 indicates AMI) 
AMI    
   No Ref Ref Ref 
   Yes 0.02 (0.00, 0.04) 0.03 (0.01, 0.05) 0.02 (0.01, 0.04) 
AMI * State Excise Tax 0.01 (-0.00, 0.03) 0.00 (-0.01, 0.02) -0.00 (-0.02, 0.02) 
State Excise Tax5 -0.01 (-0.02, 0.00) -0.01(-0.02, 0.01) -0.01 (-0.02, 0.01) 
Tobacco Control Index -0.00 (-0.01, 0.01) -0.00 (-0.01, 0.01) -0.00 (-0.01, 0.00) 
 
2. Number of Days Smoked Cigarettes (Past 30-Days) 
 Threshold: 60 
(<60 indicates AMI) 
Threshold: 68 
(<68 indicates AMI) 
Threshold: 76 
(<76 indicates AMI) 
AMI    
   No Ref Ref Ref 
   Yes 0.05 (0.01, 0.09) 0.04 (0.00, 0.07) 0.02 (-0.02, 0.06) 
AMI * State Excise Tax -0.01 (-0.04, 0.03) 0.00 (-0.03, 0.04) 0.01 (-0.03, 0.05) 
State Excise Tax5 -0.03 (-0.06, -0.00) -0.03(-0.07, -0.00) -0.04 (-0.08, -0.01) 
Tobacco Control Index -0.00 (-0.02, 0.01) -0.00 (-0.02, 0.01) -0.00 (-0.02, 0.01) 
 
3. Cigarettes Per Day (Past 30-Days) 
 Threshold: 60 
(<60 indicates AMI) 
Threshold: 68 
(<68 indicates AMI) 
Threshold: 76 
(<76 indicates AMI) 
AMI    
   No Ref Ref Ref 
   Yes 0.09 (0.02, 0.16) 0.05 (-0.01, 0.12) 0.05 (-0.01, 0.12) 
AMI * State Excise Tax 0.01 (-0.04, 0.06) -0.00 (-0.05, 0.05) 0.01 (-0.04, 0.07) 
State Excise Tax5 -0.03 (-0.07, 0.01) -0.03(-0.09, 0.02) -0.04 (-0.10, 0.02) 
Tobacco Control Index -0.01 (-0.03, 0.01) -0.00 (-0.03, 0.02) -0.00 (-0.03, 0.02) 
 
  
 100 
 
4. Total Consumption (Past 30-Days) 
 Threshold: 60 
(<60 indicates AMI) 
Threshold: 68 
(<68 indicates AMI) 
Threshold: 76 
(<76 indicates AMI) 
AMI    
   No Ref Ref Ref 
   Yes 0.09 (0.01, 0.16) 0.05 (-0.02, 0.11) 0.05 (-0.02, 0.12) 
AMI * State Excise Tax 0.02 (-0.04, 0.07) -0.01 (-0.05, 0.07) 0.02 (-0.04, 0.08) 
State Excise Tax5 -0.05 (-0.09, 0.01) -0.05 (-0.11, 0.02) -0.06 (-0.12, 0.01) 
Tobacco Control Index -0.01 (-0.04, 0.02) -0.01 (-0.03, 0.02) -0.01 (-0.03, 0.02) 
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Scoring Components of the American Lung Association’s State of Tobacco Control Report94 
 
Scoring Factor Components 
Tobacco Prevention and 
Control Spending 
Total composite score based on each state’s spending in the following 
categories, relative to the state-specific recommendation provided annually 
by the Centers for Disease Control and Prevention (CDC). 
1) State and Community Interventions 
2) Health Communication Interventions 
3) Cessation Interventions 
4) Surveillance and Evaluation 
5) Administration and Management 
Smokefree Air Laws Score is a composite based on comprehensiveness of smokefree air 
requirements across a variety of setting such as schools, private and 
government-owned workspaces, and entertainment spaces, among others. 
Access to Cessation 
Coverage  
(2008 and 2010) 
Cessation Coverage (available for 2008 and 2010) scores represent each 
state’s coverage of evidence-based cessation support, particularly for low-
income and Medicaid-eligible residents. 
Youth Access  
(2002-2006) 
Scores are based on factors such as minimum age to purchase, packaging, 
and enforcement mechanisms for such policies, among others. 
Excise Tax Rates 
(Not included in model 
results presented in this 
paper) 
Scores are assigned in quintiles based on each state’s excise tax rate for 
cigarettes compared to the mean rate among all states during each survey 
period. 
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Sensitivity Analysis for Measurement of Price Variation 
 
Table 1. Associations between Variation in AMI Symptoms, Price, and Smoking Behavior among NLSY97 Participants (2002-2010) 
 Smoking 
Participation 
n=7,087 
Number of Days 
Smoked Cigarettes 
ß (95% CI) 
n=2,599 
Cigarettes Per 
Day 
ß (95% CI) 
n=2,555 
Total Cigarette 
Consumption 
ß (95% CI) 
n=2,529 
Real Cost Per Pack     
AMI     
   No Ref Ref Ref Ref 
   Yes 0.06 (-0.13, 0.02) 0.12 (0.01, 0.24) -0.02 (-0.27, 0.24) -0.03 (-0.30, 0.25) 
AMI * Cost per Pack 0.06 (0.01, 0.12) -0.08 (-0.16, 0.01) 0.09 (-0.10, 0.28) 0.10 (-0.11, 0.30) 
Average Cost Per Pack -0.04 (-0.09, 0.01) -0.13 (-0.22, -0.04) -0.15 (-0.36, 0.05) -0.21 (-0.43, 0.01) 
Tobacco Control Index -0.01 (-0.01, 0.01) -0.01 (-0.02, 0.01) -0.01 (-0.03, 0.02) -0.01 (-0.03, 0.02) 
Excise Tax     
AMI     
   No Ref Ref Ref Ref 
   Yes 0.04 (0.02, 0.05) 0.01 (-0.01, 0.03) 0.10 (0.06, 0.15) 0.11 (0.06, 0.16) 
AMI * State Excise Tax 0.01 (-0.01, 0.02) -0.01 (-0.03, 0.01) 0.01 (-0.04, 0.05) 0.01 (-0.04, 0.07) 
State Excise Tax -0.01 (-0.01, 0.01) -0.02 (-0.03, -0.01) -0.01 (-0.06, 0.03) -0.03 (-0.07, 0.02) 
Tobacco Control Index -0.01 (-0.01, 0.01) -0.01 (-0.02, 0.01) -0.01 (-0.03, 0.02) -0.01 (-0.03, 0.02) 
Bolded p-values indicate statistical significance <0.05. 
Notes:  
1. Fixed effects Poisson regressions tested associations between smoking behavior, AMI, and state tax rates over time. All models adjusted for 
sociodemographic and time covariates. 
2. Number of days smoked refers to the number of days within the past 30-days a participant smoked cigarettes. 
3. Cigarettes per day represents the average number of cigarettes smoked on days smoking in the past 30-days. 
4. Total consumption in the past 30-days was constructed by multiplying the number of cigarettes smoked per day by the number of days a 
participant smoked cigarettes in the past 30 days. 
5. Real cost per pack obtained from Orzechowski and Walker’s The Tax Burden on Tobacco, 1970-2018. (https://chronicdata.cdc.gov/Policy/The-
Tax-Burden-on-Tobacco-1970-2018/7nwe-3aj9). 
6. State Excise Tax is the tax rate facing each participant during each survey period. 
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Sensitivity Analysis for Inclusion of Prior Smoking Behavior to Account for Addictive Potential of Cigarettes 
 
Table 1. Associations between Variation in AMI Symptoms, Excise Tax, Prior Smoking, and Smoking Behavior among NLSY97 Participants 
(2004-2010) 
 Smoking 
Participation 
ß (95% CI) 
n=6,998 
Number of Days 
Smoked Cigarettes 
ß (95% CI) 
n=1,806 
Cigarettes Per 
Day 
ß (95% CI) 
n=1,783 
Total Cigarette 
Consumption 
ß (95% CI) 
n=1,744 
Prior Tobacco Use     
Behaviort-1 -0.08 (-0.10, -0.06) -0.01 (-0.01, -0.01) -0.01 (-0.01, -0.01) -0.01 (-0.01, -0.01) 
AMI     
   No Ref Ref Ref Ref 
   Yes 0.03 (0.01, 0.04) 0.20 (-0.01, 0.04) 0.10 (0.05, 0.16) 0.10 (0.05, 0.16) 
AMI * ln(State Excise Tax) 0.01 (-0.01, 0.02) 0.01 (-0.01, 0.03) 0.04 (-0.02, 0.10) 0.05 (-0.01, 0.12) 
ln(State Excise Tax) -0.01 (-0.02, 0.01) -0.02 (-0.04, 0.01) -0.02 (-0.08, 0.03) -0.04 (-0.10, 0.02) 
Tobacco Control Index -0.01 (-0.01, 0.01) -0.01 (-0.02, 0.01) -0.02 (-0.04, 0.01) -0.02 (-0.05, 0.01) 
Without Prior Tobacco Use     
AMI     
   No Ref Ref Ref Ref 
   Yes 0.03 (0.01, 0.04) 0.01 (-0.01, 0.03) 0.11 (0.06, 0.16) 0.12 (0.06, 0.17) 
AMI * State Excise Tax 0.01 (-0.01, 0.02) -0.01 (-0.03, 0.02) 0.02 (-0.03, 0.07) 0.04 (-0.02, 0.09) 
ln State Excise Tax -0.01 (-0.02, 0.01) -0.02 (-0.04, -0.01) -0.02 (-0.07, 0.02) -0.04 (-0.09, 0.01) 
Tobacco Control Index -0.01 (-0.01, 0.01) -0.01 (-0.01, 0.01) -0.01 (-0.04, 0.02) -0.01 (-0.04, 0.02) 
Bolded p-values indicate statistical significance <0.05. 
Notes: 
1. Fixed effects linear and Poisson regressions tested associations between smoking behavior, AMI, and state tax rates over time. All models 
adjusted for sociodemographic and time covariates. Years included in all models were 2004-2010 to allow for congruence between models (2002 
not included because no lagged value of behavior available for time period one). 
2. Prior tobacco use refers to use in the previous period for each participant.  
3. Number of days smoked refers to the number of days within the past 30-days a participant smoked cigarettes. 
4. Cigarettes per day represents the average number of cigarettes smoked on days smoking in the past 30-days. 
5. Total consumption in the past 30-days was constructed by multiplying the number of cigarettes smoked per day by the number of days a 
participant smoked cigarettes in the past 30 days. 
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Electronic Cigarettes 
 Electronic cigarettes (e-cigarettes), also referred to as electronic vapor 
products or electronic nicotine delivery systems (ENDS), are battery-
operated devices that produce an inhalable aerosol by heating liquid (e-
liquid) that frequently contains nicotine, different flavoring alternatives, and 
many other chemicals. Different designs abound: some e-cigarettes are 
designed to mimic the look and feel of a conventional cigarette or other 
combustible product, others are made to resemble items such as pens or devices such as a USB drive, and some 
users purchase fillable tank systems. Despite variations in design, and whether they are disposable or reusable 
and refillable, these devices generally all have some type of reservoir (to hold e-liquid), a battery or power 
source, a heating element, and a mouthpiece. There are currently over 450 e-cigarette brands available to 
users.174 Research suggests that e-cigarettes may be less harmful than combustible cigarettes, but that they are 
not free from risk.109,175,176 E-cigarettes are increasingly popular among youth and young adults in the 
U.S.,177,178 and since they frequently contain nicotine, this has raised concern that initiating e-cigarette use could 
also lead to later use of combustible products.179 The U.S. FDA finalized rules in 2016 extending its regulatory 
authority to electronic vapor products such as e-cigarettes, and continues to evaluate policy options to regulate 
these products.17,180 
 
Low Nicotine Cigarettes  
  
 Low nicotine cigarettes are combustible cigarettes in which the nicotine content in the cigarette has been 
reduced by the manufacturer from levels of nicotine in conventional production. Manufacturers can achieve this 
outcome by creating tiny ventilation holes to reduce a smoker’s intake of nicotine when smoking, or through 
incorporating lower-nicotine tobacco into their cigarettes.145 The U.S. FDA is currently considering a policy 
strategy that would require cigarette manufacturers to reduce the concentration of nicotine in cigarettes to 
reduce the addictive potential (abuse liability) of combustible cigarettes,117 though that policy initiative has 
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recently been postponed.181 This policy strategy signals to the public that, while addictive regardless of how it is 
delivered to the user, the methods of ingesting nicotine are not all equal in terms of expected risk from the 
perspective of the FDA.16 For example, while a smoker could theoretically choose to consume a specific 
amount of nicotine each day via consumption of their traditional brand of combustible cigarette, they could also, 
in theory ingest that same amount of nicotine through use of an electronic vapor product, yet face different risks 
to their health over the long term. While e-cigarettes, for example, are not without health risk, they are widely 
considered to be less harmful than combustible cigarettes.109,175,176 Incorporating combustible cigarettes with 
lower abuse liability into the market could encourage smokers to switch to less harmful alternatives, however 
further evidence is required to form expectations about exactly how smokers would respond to such a shift. 
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Study Screener (restricted to adults ages 18+ who use a U.S-based IP address) 
 
1. Are you over the age of 18? 
a. Yes 
b. No (If no, ineligible) 
 
2. Have you ever smoked a cigarette, even one or two puffs?  
a. Yes 
b. No (If no, ineligible) 
 
3. Do you now smoke cigarettes: 
a. Every Day 
b. Some Days 
c. Not at All (if Not at All, ineligible) 
 
4. How many cigarettes have you smoked in your entire life? A pack usually has 20 cigarettes. 
a. 1 or more puffs but never a whole cigarette 
b. 1-10 cigarettes (less than or equal to half of a pack) 
c. 11-20 cigarettes (1/2 to 1 whole pack) 
d. 21-50 cigarettes 
e. 51-99 cigarettes/100 or more cigarettes (5 packs or more)  (if fewer than 100, ineligible) 
 
5. Over the last 2 weeks, how often have you been bothered by any of the following problems? 
a. Little interest or pleasure in doing things 
i. Not at all 
ii. Several days 
iii. More than half the days 
iv. Nearly every day  
 
b. Little interest or pleasure in doing things 
i. Not at all 
ii. Several days 
iii. More than half the days 
iv. Nearly every day 
 
(Not at all=0 and Nearly every day=3. Generate total score for 4a and 4b, score lower than 3 deemed “No 
AMI” and score 3 or greater deemed “AMI).124 
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Own Brand Cigarette Purchase Task 
Imagine a TYPICAL DAY during which you smoke. The following questions ask how many times 
you would take 10 puffs of your own brand of cigarettes if they cost various amounts of money. The 
only available cigarettes are your own brand. Assume that you have the same income/savings that 
you have now and NO ACCESS to any cigarettes or nicotine products other than those offered at 
these prices. In addition, assume that you would consume cigarettes that you request on that day; 
that is, you cannot save or stockpile cigarettes for a later date. Please respond to these questions 
honestly. 
 
[Please note the following two sentences will be displayed for each of the X prices below. 
Participants will continue on this task until either they make purchases at all of the prices, or they 
elect to purchase zero on two successive prices] 
 
-If 10 puffs of your own brand of cigarettes cost X: How many times would you buy 10 puffs to 
consume in one day? 
 
- You would buy 10 puffs of your own brand of cigarettes Y times if they cost X each? 
1= Yes 
2 = Change Answer 
 
Y times you would buy 10 puffs of your 
own brand cigarette (numeric response by 
participant) 
X (price) 
 $0 (free) 
 $0.01 
 $0.02 
 $0.04 
 $0.08 
 $0.16 
 $0.32 
 $0.64 
 $1.28 
 $2.56 
 $3.84 
 $5.12 
 $6.40 
 $7.68 
 $8.96 
 $10.24 
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Cross-product Cigarette Purchase Task: Note-This task was performed four times: once for each of the four 
alternatives products. The low nicotine combustible cigarette condition is shown below. 
Instructions: Now imagine another TYPICAL DAY during which you smoke. The following 
questions ask how many times you would take 10 puffs of a cigarette or 10 puffs of a cigarette with 
half the amount of nicotine as your own-brand cigarette if your brand cigarettes cost various 
amounts of money. The available cigarettes are your own brand. Assume that you have the same 
income/savings that you have now, but this time, assume that 10 puffs of the low nicotine cigarette 
are also available at a fixed price of $1. In addition, assume that you would consume the products 
that you request on that day. That is, you cannot save or stockpile cigarettes or low nicotine 
cigarettes for a later date. Please respond to these questions honestly. 
 
[Please note the following two sentences will be displayed for each of the X1/X2 prices below. 
Participants will continue on this task until either they make purchases at all of the prices, or they 
elect to purchase zero on two successive prices] 
 
-If 10 puffs of your own brand of cigarettes cost X1 and 10 puffs of a low nicotine cigarette cost X2: 
How many times would you buy 10 own brand puffs and/or 10 puffs of the low nicotine cigarette to 
consume in one day? 
 
- You would buy 10 puffs of your own brand of cigarettes Y1 times if they cost X1 each and 10 
puffs of the low nicotine cigarette puffs Y2 times if they cost X2 each? 
1= Yes 
2 = Change Answer 
Y1 times you would 
buy 10 puffs of your 
own brand cigarette 
(numeric response by 
participant) 
X1 (own brand price) Y2 times you would 
buy 10 puffs of a low 
nicotine cigarette 
(numeric response by 
participant) 
X2 (low 
nicotine 
cigarette price) 
 $0 (free)  $1.00 
 $0.01  $1.00 
 $0.02  $1.00 
 $0.04  $1.00 
 $0.08  $1.00 
 $0.16  $1.00 
 $0.32  $1.00 
 $0.64  $1.00 
 $1.28  $1.00 
 $2.56  $1.00 
 $3.84  $1.00 
 $5.12  $1.00 
 $6.40  $1.00 
 $7.68  $1.00 
 $8.96  $1.00 
 $10.24  $1.00 
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The following tables provide information about the role of model choice in predicting key coefficients of 
interest in models of smoking behavior. 
 
Table 1. Total Cigarette Consumption 
 Pooled OLS Random Effects Fixed Effects Fixed Effects (AMI 
Time Invariant) 
AMI -0.15 (-0.24, 0.06) -0.03 (-0.11, 0.06) 0.05 (-0.05, 0.14) -- 
AMI*High 
Dependence 
0.22 (0.12, 0.33) 0.12 (0.02, 0.22) 0.06 (-0.05, 0.17) 0.17 (0.03, 0.31) 
High Dependence 0.68 (0.62, 0.74) 0.54 (0.48, 0.60) 0.27 (0.20, 0.35) 0.20 (0.10, 0.,31) 
 
Internalizing 0.04 (-0.07, 0.14) 0.05 (-0.05, 0.15) 0.03 (-0.08, 0.15) -- 
Internalizing * High 
Dependence 
-0.03 (-0.10, 0.15) 0.06 (-0.06, 0.18) 0.10 (-0.03, 0.24) 0.14 (-0.03, 0.30) 
Externalizing -0.28 (-0.41, -0.16) -0.12 (-0.22, -0.01) 0.03, -0.08, 0.15) -- 
Externalizing * High 
Dependence 
0.30 (0.15, 0.44) 0.09 (-0.05, 0.23) -0.08 (-0.23, 0.08) 0.05 (-0.12, 0.22) 
High Dependence 0.69 (0.63, 0.75) 0.55 (0.49, 0.61) 0.28 (0.20, 0.36) 0.21 (0.11, 0.31) 
 
 
Regarding total cigarette consumption, the pooled model reveals a significant negative association between 
experiencing any AMI symptoms and consumption, as well as a positive association for the moderating effect 
of AMI on the association between high dependence and cigarette consumption, and for high dependence alone 
(Table 1, Column 1). A random effects model takes into account the panel structure of the data, which reduces 
the magnitude and statistical significance of the association between AMI and consumption and reduces the 
magnitude of the significant association between an interaction between AMI and high dependence, and high 
dependence alone (Column 2). However, a random-effects model uses information from both within and 
between participants, therefore it does not control for unobservable and time-invariant, individual-level factors 
that are known to be associated with variation in consumption, such as sex, race/ethnicity, highest educational 
attainment, cultural attitudes about tobacco use, tobacco policies to which a participant would be subject, and 
peer and family smoking.  
 
The fixed effects model reveals that once we try to account for time-invariant factors at the participant level, 
only high dependence is significantly associated with consumption, and the magnitude of that association is 
reduced again (Column 3). These patterns are similar across the two other smoking behavior outcomes 
measured in this study, making a quit attempt and achieving self-reported cessation (Tables 2 and 3, below).  
 
The weakness of the fixed effect model is that it relies upon data from those who have experienced a change in 
their AMI status during the study period, and it relies upon the precision of the instrument measuring AMI to 
accurately capture the presence or absence of symptoms as they may influence coping behaviors such as 
smoking. A number of other studies have employed a lifetime measure of AMI, as many individuals who 
experience symptoms of AMI may do so more than once in their lifetimes, for any extended period of time 
without or before diagnosis or treatment, and the severity of symptoms may fluctuate. Models summarized in 
column 4 employed fixed effects and allowed AMI to be ‘fixed’ during the study period for any participant who 
experienced symptoms during the four time periods during which data were collected. This is more closely 
aligned with an approach, taken in several previous studies in this area, that would employ lifetime AMI to 
represent mental health. In doing so, we observed that highly dependent smokers, and highly dependent 
smokers with AMI smoked more cigarettes than those with low dependence and no AMI symptoms. The 
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weakness of an approach that employs lifetime AMI, or any AMI during the study period, is that it allows for 
confusion about temporality under certain conditions, such as those in which a participant who smokes across 
all waves without AMI symptoms may experiences a stressful life event during Wave 4 data collection and be 
classified as having AMI during that period, and therefore all periods under this approach.  
 
Of all 3,919 participants who experienced AMI during the four waves of the PATH Study used in this analysis, 
357 participants in the sample met this criterion (9%). Of those 357 participants, 51 had reported that they had 
quit smoking (and not resumed) before Wave 4 data collection, therefore the number of participants for whom 
this scenario would be a threat to our overall interpretation was relatively small.  Finally, in models employing a 
time carrying measure of AMI, disaggregating internalizing from externalizing symptoms revealed that 
significant associations between AMI and consumption appeared to be largely driven by experience of 
externalizing symptoms (impulsivity or behavior disorders), whereas a time-invariant fixed effects model 
revealed that experience of internalizing symptoms was most significantly associated with reduced success in 
achieving self-reported cessation.  
 
 
 
Table 2. Probability of Making a Quit Attempt 
 Pooled OLS Random Effects Fixed Effects Fixed Effects 
(AMI Time 
Invariant) 
AMI -0.06 (-0.04, 0.09) 0.05 (0.03, 0.07) 0.01 (-0.02, 0.03) -- 
AMI*High 
Dependence 
-0.03 (-0.06, -0.01) -0.02 (-0.05, 0.01) -0.00 (-0.04, 0.03) -0.01 (-0.05, 0.04) 
High Dependence -0.00 (-0.02, 0.01) -0.01 (-0.02, 0.01) -0.02 (-0.05, 0.00) -0.02 (-0.05, 0.01) 
 
Internalizing 0.03 (0.01, 0.06) 0.02 (-0.01, 0.05) -0.02 (-0.05, 0.01) -- 
Internalizing * High 
Dependence 
-0.02 (-0.05, 0.02) -0.01 (-0.04, 0.03) 0.02 (-0.02, 0.06) 0.01 (-0.04, 0.06) 
Externalizing 0.07 (0.04, 0.10) 0.06 (0.03, 0.09) 0.04 (0.01, 0.07) -- 
Externalizing * High 
Dependence 
-0.03 (-0.07, 0.01) -0.03, -0.07, 0.01) -0.03 (-0.08, 0.01) -0.03 (-0.08, 0.02) 
High Dependence -0.00 (-0.02, 0.01) -0.01 (-0.02, 0.01) -0.02 (-0.05, 0.00) -0.01 (-0.04, 0.02) 
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Table 3. Probability of Achieving Self-Reported Cessation 
 Pooled OLS Random Effects Fixed Effects Fixed Effects (AMI 
Time Invariant) 
AMI 0.02 (0.01, 0.04) 0.02 (0.01, 0.03) -0.00 (-0.02, 0.02) -- 
AMI*High 
Dependence 
-0.06 (-0.07, -0.04) -0.05 (-0.06, -0.03) -0.02 (-0.04, 0.00) -0.04 (-0.06, -0.01) 
High Dependence -0.01 (-0.02, -0.01) -0.01 (-0.02, -0.01) 0.01 (-0.00, 0.03) 0.03 (0.01, 0.05) 
 
Internalizing 0.01 (-0.01, 0.03) 0.01 (-0.01, 0.03) -0.01 ( -0.02, 0.02) -- 
Internalizing * High 
Dependence 
-0.04 (-0.06, -0.02) -0.04 (-0.06, -0.02) -0.02 (-0.04, 0.01) -0.04 (-0.07, -0.02) 
Externalizing 0.02 (-0.00, 0.04) 0.02 (-0.00, 0.03) 0.01 (-0.02, 0.03) -- 
Externalizing * High 
Dependence 
-0.03 (-0.05, -0.01) -0.02 (-0.05, -0.00) -0.01 (-0.04, 0.02) -0.02 (-0.05, 0.01) 
High Dependence -0.02 (-0.02, -0.01) -0.01 (-0.02, -0.01) 0.,01 (-0.00, 0.03) 0.03 (0.01, 0.05) 
 
